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ABSTRACT 
Exosomes are small vesicles with immune-stimulatory capacity, which can activate T cell 
responses in a B cell dependent manner, and therefore may serve as immune therapeutic tools. 
Peptide-loaded dendritic cell (DC)-derived exosomes are proven safe in clinical trials, although 
with limited ability to induce cytotoxic T lymphocyte (CTL) responses or prolong patient 
survival. Therefore, we aimed to investigate the role of exosomal MHC/peptide complexes in 
immune activation and explore how to enhance exosome induced immunotherapies by 
applying additional stimuli to the exosomes. Bone marrow-derived dendritic cell (BMDC) 
exosomes loaded with ovalbumin (OVA) and α-galactosylceramide (αGC) were used for this 
purpose. Exosomes lacking major histocompatibility complex (MHC) class I or those that were 
MHC mismatched were thoroughly studied in vivo for their ability to stimulate effector T cells 
and humoral responses. In addition, we applied a novel strategy, lyophilization, for exosomal 
loading of antigen and adjuvants. Here, OVA, CpG-ODN and αGC were added to RAW 264.7-
derived exosomes and assessed for their immune-stimulatory capacity. We demonstrated that 
exosomal MHC/peptide complexes were redundant for T cell stimulation in vivo in the 
presence of whole OVA, as MHCI-/- and allogeneic exosomes could successfully induce CD8+ 
T cell responses and inhibit tumor progression (study I). Importantly, allogeneic exosomes 
served as an adjuvant by the upregulation of T follicular helper (Tfh) cells and increased 
antigen-specific antibody production (study II). We also discovered that lyophilization was 
feasible for loading exosomes without markedly altering exosome characteristics. Notably, 
additional use of the TLR9 ligand CpG-ODN improved their immune-stimulatory properties 
and achieved tumor regression (study III). 
Selective loading and accumulation of certain tissue-specific proteins and RNA into exosomes 
provides a platform for potential biomarker analysis, the advantages of which include the 
accessibility of vesicles in body fluids (“liquid biopsies”), and the ability to trace cellular origin. 
However, limited material often restricts exosome proteomic analyses. Therefore, we aimed at 
applying the highly sensitive proximity extension assay (PEA) on cell line- and body fluid-
derived exosomes to investigate the potential of using PEA for exosome protein evaluation. 
We confirmed that PEA can be applied on exosomes to trace their cellular source and to identify 
accumulated vesicle proteins. Also, the protein content of the body fluid-derived exosomes 
from breast milk and seminal fluid displayed diverse protein profiles (study IV), suggesting the 
cell/tissue traceability of exosomes by PEA and motivating their future use as biomarkers. 
In conclusion, this thesis provides increased understanding of the mechanisms underlying 
exosome-based immunotherapies and suggests the use of impersonalized exosomes and 
allogenicity as a possible means of enhancing their immune-stimulatory effects in a clinical 
setting. In addition, this thesis offers insight into novel technologies for improved exosomal 
loading and the use of PEA for exosome proteomic research. 
 
  
POPULAR SCIENCE SUMMARY 
The immune system, or “the soldiers of the body” is important to protect us from various 
diseases such as bacterial and viral infections, and for removing potentially dangerous cells like 
cancer cells. This thesis investigates “exosomes”, small lipid droplets released by all cells in 
the body, which are interesting to study since they can control the immune system and both 
start or stop immune responses.  
We aimed at exploring the use of exosomes in cancer treatment, so called immune therapy, 
with the purpose to activate and instruct the immune system to kill tumor cells. The potential 
use of exosomes as cancer immunotherapy have previously been explored in clinical trials. We 
know that they are safe to give to patients. However, we have not yet managed to optimize the 
efficacy of the exosome therapies, and we still lack the full knowledge how to improve 
exosome-induced cancer cell elimination. Therefore, we used mouse models to learn more 
about how exosomes activate immune responses and how we can change them to make them 
more efficient. Initially, exosomal therapy was based on using the patient’s own immune cells, 
collecting and loading exosomes with a small protein piece “peptide” and then giving the 
exosomes back to the patient. We have generated scientific evidence in our mouse models 
suggesting that exosomes originating from one type of immune cell, the dendritic cells, can be 
used from other donors and does not have to come from the patient’s themselves. Dendritic 
cells direct immune responses and exosomes derived from these cells share this property. In 
addition, exosomes can also be actively loaded to deliver proteins or other molecules within 
the body. We also used a novel method to add stimulatory molecules to the exosomes for an 
enhanced immune cell activation and better responses against the cancer.  
Exosomes can be found in many different body fluids, e.g. blood, breast milk and urine and are 
therefore easy to access. They transport information between cells and interestingly this 
information can control the function of the recipient cell. The exosomal cargo reflects the cell 
it comes from, like a tiny “mirror image” of their parental cell. However, exosome content is 
not always a complete copy of their origin. In fact, some exosomal transported material 
accumulates inside the exosomes. Exosomes are therefore exciting to study as they can provide 
knowledge about diseases for example cancer, and potentially serve as diagnostic and 
prognostic markers. In this thesis, we also examined a novel and more sensitive method to map 
the exosome protein content. This method can be applied in future studies with the aim to find 
specific disease markers so called “biomarkers”. 
In conclusion, we demonstrate that we can use unpersonalized exosomes in cancer 
immunotherapy. This will hopefully make exosome-based treatment more efficient, and 
accessible, which would be beneficial for the patient. In addition, better disease markers would 
provide earlier and individualized treatment which will further improve the patient prognosis. 
These approaches are also more cost efficient for the society. The future goal would be the 
possibility to not only use exosomes as cancer treatment but also as preventive vaccines to 
avoid development of cancer.
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1 INTRODUCTION 
This part serves to provide a background to the immune system in general and also more 
specifically on the research topic of this thesis, namely exosomes and their role in the immune 
system, in immunotherapy and the use of exosomes as diagnostic markers for disease. 
1.1 The immune system 
The role of the immune system is to protect the host from invading pathogens such as viruses, 
bacteria and fungi. A multitude of cells with different properties are working together with 
specific proteins in an organized network to prevent and clear infections. The immune 
response is always dependent on a balance between defending the host, and to know when to 
switch off the response. This balance is clearly visualized when it comes to allergies and 
autoimmune diseases, caused by an increased activity of the immune system or 
misinterpretation of the information received. After an immune activation towards a specific 
pathogen an immune memory will arise, i.e. long-lived antigen-specific lymphocytes, which 
upon re-challenge with the same pathogen will mount a more efficient response. To simplify 
the function of the immune system it is generally divided into two parts; the innate immunity 
that is quick, non-specific and lack memory and the adaptive immunity that takes longer time 
to respond, is highly specific and can form a long-lasting memory. Both parts are indeed 
dependent on each other and some of their activity is in the grey zone bridging these two (1, 
2). 
1.2 The innate immune system 
The natural protection provided by the innate immune system is the epithelial barriers, e.g. 
the skin, gastrointestinal tract and lungs where naturally occurring antimicrobial proteins and 
specialized immune cells are localized. The strategy of the innate immunity is to express a 
broad range of germline-encoded so called pattern-recognition receptors (PRR), which have 
evolved towards recognizing conserved regions solely present on the pathogens and not on 
host cells. In response to microbial presence, the innate immunity will sense their foreign 
surface structures, termed pathogen-associated molecular patterns (PAMPs), e.g. 
lipopolysaccharides (LPS), double-stranded ribonucleic acid (RNA), peptidoglycans, 
mannose, bacterial DNA CpG oligodeoxynucleotides (ODN) and glucans (3, 4). Another 
recognition pathway is activated by stressed cells which release molecules, called damage-
associated molecular patterns (DAMPs) that can be sensed by immune cells, e.g. phagocytes 
and dendritic cells (DCs) but also by epithelial and endothelial cells. Several classes of PRRs 
exist, one of them that is crucial for pathogen recognition is the Toll-like receptor (TLR) 
family. Among those, TLR4, one of the first TLRs to be discovered, is able to recognize 
bacterial LPS (5), TLR9 on the other hand, recognizes unmethylated CpG-ODN (6). 
Neutrophils and monocytes are circulating innate immune cells that can phagocytose 
microbes in the circulation. They are also recruited to the site of infection by adhering to the 
endothelium with the aid of specific adhesion markers, integrins and selectins, and migrate 
through the endothelium to the infected tissue site. Upon migration of monocytes into the 
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tissue, they can differentiate into macrophages. The tissue-resident macrophages produce 
cytokines including tumor necrosis factor (TNF)-α and interleukin (IL)-1β when they 
encounter microbes. This will upregulate endothelial adhesion markers E-selectin and P-
selectin for recruitment of circulating leukocytes to the infected site. Furthermore, antigen 
presenting cells (APC) play an important role in identifying microbes and to process and 
present the antigens to other immune cells of the adaptive immune system. They also secrete 
pro-inflammatory cytokines to provide an immunological environment that will support the 
effector cell activity (2). 
1.2.1 Natural killer cells 
Natural killer (NK) cells are bone marrow-derived lymphocytes that can identify and 
eliminate stressed and infected cells by using enzymes, e.g. perforin and granzymes, or by 
induction of death signals via first apoptosis signal ligand (FasL) or TNF-related apoptosis-
inducing ligand (TRAIL), which will induce apoptosis (7). In addition, they also secrete 
interferon (IFN)-γ to stimulate macrophage phagocytosis of pathogens (8). NK cells were 
initially described to induce antibody-dependent cellular cytotoxicity (ADCC) without 
further stimulatory signals (9). As their name “natural killer” suggests, they are programmed 
to kill cells without receiving prior immune signals. However, they do require presence of 
IFN-γ and IL-15 for the killing of tumor cells (10, 11). Major histocompatibility complex 
(MHC) can be sensed by NK cells as they are educated to recognize self-MHC molecules. 
Detection of self-MHC will engage their inhibitory signals called killer cell immunoglobulin-
like receptors (KIR). In contrast, the absence of MHC class I molecules on the cell surface 
will activate the NK cells known as the “missing-self” theory (12). 
1.2.2 Natural killer T cells 
Natural killer T (NKT) cells are categorized as innate immune cells despite sharing features 
with both NK cells and T cells, by the expression of both NK cell markers and a T cell receptor 
equivalent. They are important for adaptive immune responses, and can be subdivided into 
type I, i.e. invariant NKT (iNKT) cells or type II NKT cells. They respond to microbial lipids 
or glycolipids via their MHC-related molecule CD1. For instance, iNKT cells sense and 
respond to the glycolipid α-galactosylceramide (αGC) presented on CD1d, and are able to 
produce both T helper type (Th)1 and Th2 cytokines. In addition, they can be further 
subdivided into CD4+ and CD4- cells expressing diverse cytokine profiles, whereas sharing 
IFN-γ secretion (13). iNKT cells have an important role in Th1 immunity as they can be 
stimulated by and kill tumor cells through the release of IFN-γ, to further activate other 
immune cells (14). 
1.2.3 Dendritic cells 
In 1973, Ralph Steinman was first to describe DCs as a cell type different than macrophages 
by expressing high levels of MHC (15, 16). MHC complexes are surface expressed proteins 
important for pathogen recognition by the acquired immune system. DCs are APCs with the 
main function to process and present antigenic peptides on their MHC molecules for inducing 
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T cell activation, and they therefore serve as an important link between the innate and 
adaptive immune system. MHC class I molecules, expressed on all nucleated cells, bind 
shorter peptides, while MHC class II, expressed on APCs, bind longer peptides. Another 
important feature of DCs is their secretion of pro-inflammatory cytokines, e.g. IFN, TNF, IL-
1, IL-6 and IL-12, for leukocyte recruitment and effector cell differentiation when they 
encounter pathogens (17). Moreover, DCs can be found resident in tissues that are commonly 
exposed to pathogens, such as mucosal tissues. Upon antigen recognition, they undergo 
maturation by upregulation of costimulatory molecules, e.g. cluster of differentiation 
(CD)40, CD80 and CD86, and also expression of MHC class I and class II molecules. During 
DC maturation, they also migrate to the secondary lymphoid organ, for interaction and 
peptide presentation to T cells (16). Notably, there are many DC subsets with diverse 
phenotypes; surface marker expressions, gene expression and capabilities to induce immune 
responses (18). 
1.2.3.1 Antigen uptake and presentation by DCs 
DCs can take up antigens via receptor-mediated endocytosis, phagocytosis and 
macropinocytosis. For the receptor-mediated uptake of antigens DCs express the C-type-
lectin protein family receptors, e.g. DEC205 and the mannose receptor (MR). DCs also 
express Fc-receptors (FcRs) for internalization of immune complexes (19). After exogenous 
antigen uptake, the antigens are processed for digestion into peptides. This process occurs at 
low pH in the endocytic compartments, where MHC class II molecules are loaded with the 
peptides followed by MHC/peptide transportation to the cell surface (figure 1). In contrast, 
endogenous antigens are degraded in the proteasome for peptide generation (figure 1). The 
peptides are then transported to the endoplasmic reticulum (ER), where the MHC class I 
molecules are produced, the transport is performed by the transporter associated with antigen 
processing (TAP) proteins. Peptide loading onto the MHC class I molecules stabilizes the 
MHC/peptide complex and allows it to be presented on the cell surface (19). Although the 
mechanisms for peptide loading onto MHC class I or class II molecules are highly controlled, 
DCs also accomplish loading of exogenous antigens onto MHC class I molecules, called 
“cross-presentation”, which can lead to either tolerance induction or antigen-specific CD8+ 
T cell activation, which is an important feature for immunotherapy (20, 21). 
 4 
 
Figure 1. DCs can process antigens by different pathways for peptide loading onto MHC class I or class II 
molecules. For endogenous antigens, peptides are loaded on MHC class I molecules. Exogenous antigenic 
peptides are loaded on MHC class II molecules. DCs are also able to cross-present exogenous antigens onto 
MHC class I molecules. 
1.3 The adaptive immune system 
The adaptive immune system mediated by lymphocytes, mainly T and B cells, has a broad 
range of receptors for antigen recognition. The receptor diversity and specificity is mediated 
by somatic rearrangement of the variable regions of gene segments in a process called V(D)J 
recombination, where the variable (V), joining (J) and diversity (D) segments are joined 
together in various combinations. Thus, only a few cells will share the same antigen or peptide 
specificity, which gives rise to broad variability in cellular recognition of a certain peptide. 
Adaptive immunity is activated upon lymphocyte recognition of pathogens, which 
subsequently induce a long-lasting protection. Activation of an adaptive immune response with 
high specificity takes several days to develop, in contrast to the rapid although less specific 
innate immunity. B cells are responsible for the recognition of antigens and induction of a 
humoral response generated against many different microbe-associated proteins, 
carbohydrates, nucleic acids or lipids. In contrast, T cells can only identify protein fragments, 
peptides, presented by the APCs. Unfortunately, the adaptive immunity may also respond to 
antigens other than those present on microbes such as self-antigens or harmless molecules, 
and thus together with other cells drives diseases like autoimmunity and allergies (1). 
1.3.1 Initiating an immune response 
The primary lymphoid organs, bone marrow and thymus, are responsible for the production of 
lymphocytes, which originate from hematopoietic stem cells. Thereafter, the lymphocytes are 
trained and the immune responses are generated in the secondary lymphoid organs, e.g. spleen 
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and lymph nodes, which are strategically distributed throughout the body. The spleen is central 
when it comes to initiating an immune response against a pathogen, as both innate and adaptive 
players are present. Blood is filtered through the spleen (red pulp), allowing immune 
recognition of foreign antigens by APCs, followed by the interaction with lymphocytes to 
mount the adaptive immune response. In the lymphoid compartment of the spleen (white pulp), 
B and T cells are separated into different sites. B cells are located in follicles (B cell zone), 
which are surrounded by T cells (T cell zone). The marginal zone, between the red and the 
white pulp, contain resident cells with diverse functions; marginal zone macrophages (MZM) 
important for virus clearance, marginal zone metallophilic macrophages (MMM) that 
phagocytose microbes and also marginal zone B (MZB) cells, which upon pathogen 
recognition will produce low-affinity antibodies. Taken together, upon antigen capture an 
immune response is initiated, where APCs will activate naïve CD4+ T cells in the T cell zone. 
B cells will meet the educated T cells and they interact at the border between their 
compartments for immune activation (22). 
1.3.2 T lymphocytes 
T cells are generated in the bone marrow and mature in the thymus, where they undergo a 
strictly controlled two-step selection for antigen specificity; i) recognition of MHC 
complexes (positive selection), and ii) elimination of strong MHC self-recognition (negative 
selection) (23). Naïve T cells are frequently scanning the secondary lymphoid organs for 
recognition of antigenic peptides presented on MHC class I or class II by APCs, mainly DCs. 
Each T cell has a T cell receptor (TCR) with specificity towards a limited set of epitopes. Upon 
TCR recognition of the MHC/peptide complex and subsequent recognition of the MHC class 
I or class II molecule by the CD8 or CD4 co-receptor, respectively, a second signal is required 
for T cell activation. This occurs through costimulatory receptor CD28 interaction with its 
ligands CD80/86 on the APC. The antigen-specific T cells undergo clonal expansion and 
migration to the infectious site to exert their effector functions. In brief, peptides presented by 
MHC class I are recognized by CD8+ T cells also called cytotoxic T lymphocytes (CTL), which 
are specialized killer cells. Upon activation and stimulatory signals induced by CD4+ T cells, 
CTLs will release perforin and granzymes to induce apoptotic signals that will kill the infected 
cell. MHC class II peptides presented by professional APC, i.e. DCs, macrophages and B cells, 
are recognized by CD4+ T cells, which in turn can activate infected macrophages to eliminate 
the pathogen and induce antibody production by B cells to promote a humoral response (24). 
During a bacterial infection, antigens internalized by APCs from the extracellular environment 
will be processed and presented by MHC class II for the activation of CD4+ T cell and 
subsequent B cell antibody production will occur. In contrast, CD8+ T cell activation occurs 
when cytosolic antigens are present i.e. during a viral infection, by the recognition of MHC 
class I presented peptides (figure 1). Moreover, CD4+ T cells can be further subdivided into; 
Th1, Th2, Th17, and regulatory T cells (Tregs), among others, based on their diverse cytokine 
and transcription factor profiles. Tregs are important for induction of peripheral tolerance i.e. 
maintaining immune homeostasis by secretion of the anti-inflammatory cytokines IL-10 and 
transforming growth factor (TGF)-β for inhibition of effector T cells. In addition, they are 
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characterized by expression of the forkhead box P3 (FoxP3) transcription factor and the surface 
receptors CD25, cytotoxic T lymphocyte-associated antigen (CTLA)-4 and programmed cell 
death protein (PD)-1, among others. Consequently, reduced activity of Tregs has been linked 
chronic inflammatory diseases and autoimmunity (25). 
1.3.3 B lymphocytes 
B cells originate from and mature in the bone marrow. They undergo positive and negative 
selection, according to the same principles as described for T cells, and V(D)J recombination 
of the heavy and light chains to generate diverse B cell receptors (BCR) (26, 27). After 
successful receptor editing, mature B cells express both immunoglobulin (Ig)M and IgD 
required to exit the bone marrow and migrate to the spleen for further maturation. The 
primary function of B cells is to produce high-affinity antibodies, which can neutralize and 
opsonize pathogens for elimination by phagocytes. B cells can be activated in a T cell-
dependent manner, where B cells recognize and internalize the antigen and present it on their 
MHC class II molecules, thus serving as APCs. This will lead to B cell downregulation of 
CXCR5 and upregulation of CCR7 for migration towards the T cell zone. The signal for B 
cell activation also comes from the interaction with T follicular helper (Tfh) cells that have 
already encountered the same antigen. These are CD4+ T cells, either naïve or previously 
differentiated T cells, which have downregulated CCR7 and upregulated CXCR5 for 
migration towards the B cell zone. T cell recognition of the MHC class II peptide presented 
by the B cell is important for B cell activation, generation of memory B cells and high-affinity 
antibody production (28). The majority of the B cells are located in the secondary lymphoid 
organs where the germinal center formation occurs. Here, the antigen-specific B cells 
undergo clonal expansion, Ig isotype class switching and affinity maturation. With enzymatic 
help, somatic hypermutation induce point mutations in the variable region for affinity 
maturation, and different antibody subclasses are generated through editing of the constant 
region of the heavy chains (29). Follicular B (FOB) cells are the majority of B cells in 
lymphoid organs. They undergo class switch and can give rise to long-lived plasma cells. 
Another activation pathway is induced by polymeric antigens such as carbohydrates in a T 
cell-independent manner, without the help from Tfh cells, the B cells secrete IgM antibodies 
and no class switching will occur. The innate-like MZB cells, located in the marginal zone 
respond to blood-derived antigens in a T cell-independent manner (30). Moreover, B cells 
are assisted by follicular dendritic cells (FDC) for antigen presentation and antigen-driven 
selection of high-affinity B cells, although not via MHC molecules but through complement 
or FcRs (31). In addition, the Tfh cells, a specific subclass of CD4+ T cells previously 
activated by DCs, support the selection of high-affinity germinal center B (GC B) cells by 
providing survival signals and promote antibody production, these cells may enter the 
circulation to become long-lasting antibody secreting plasma cells (32). 
1.3.4 Antibodies 
Antibodies, also called immunoglobulins, are proteins that occur both as membrane bound 
BCRs on B cells or as secreted forms. Thus, a major function of B cells is to produce antibodies 
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that can eliminate pathogens (2). The antibody itself consists of two heavy- and two light 
chains, both having a constant (C) and a variable (V) region, where the variable regions 
together create the antigen recognition part, the fragment antigen binding (Fab). The residual 
part of the antibody is the fragment crystalline (Fc) region responsible for the biological 
activity of the antibody as the cells have Fc receptors (FcR) for antibody binding (33). 
Overall, there are five Ig classes; IgM, IgD, IgA, IgE, and IgG with diverse properties (33). 
IgM is the first antibody produced, which can eliminate pathogens in the early immune 
response. IgD can stimulate immune cells such as basophils and mast cells. Both IgM and 
IgD are expressed on naïve B cells. IgA is important for toxin and microbe elimination and 
is mainly found in mucosal tissue sites, e.g. the gastrointestinal tract. IgE is important in the 
defense against helminths, but is also linked to acute allergic responses. IgG is the primary 
isotype found in blood, which is important for opsonization and subsequently elimination of 
pathogens by macrophage phagocytosis or induction of ADCC mediated killing by NK cells. 
The group of IgGs can be further divided into several subclasses in humans; IgG1, IgG2, 
IgG3 and IgG4, and in mice; IgG1, IgG2a, IgG2b, IgG2c and IgG3, all with different effector 
functions (34). 
1.4 Tumor immunology 
The immune system is central in controlling and regulating cancer development, by the 
recognition of tumor cells, inhibition of tumor progression by tumor cell killing and to avoid 
the spreading of escaping tumor cells. In contrast, in the tumor microenvironment (TME) itself, 
immune cells often support the tumor growth by selecting tumor cell survival and thus 
inevitably driving tumor progression (35). Paul Ehrlich was first to discuss the role of cancer 
in relation to the host immunity in 1909 (35, 36). Since then, based on the evidence of host 
immunity against tumor antigens, the immunological control of cancer has been extensively 
investigated (37). However, the term “immunosurveillance”, i.e. the immune control of the 
tumor, was questioned until the 1990´s, when IFN-γ was shown important for the control of 
tumor establishment (38). In an immunocompetent individual, the tumor environment is 
constantly edited by the immune system, which will lead to the selection of resistant tumor 
cells that are able to cope with the hostile environment (39). Immunoediting can be divided 
in three stages; i) immune recognition and elimination of tumor cells, ii) controlled tumor 
growth balanced between the tumor and the host, and iii) tumor transformation and escape 
of host detection (35, 40, 41). Evidently, immune recognition of tumor and action towards 
elimination is linked to patient prognosis, for example tumor infiltrating lymphocytes 
producing IFN-γ and TNF-α is favorable for inhibiting tumor progression (38, 39, 42). 
Tumors may express epitopes that are different from those present on healthy cells, these are 
called tumor antigens or “neoantigens” (43). These proteins are transformed (mutated) or 
overexpressed cellular antigens (35). Neoantigens may serve as targets when designing novel 
treatment strategies as they have been identified for several malignancies, although, varying 
mutation rates thus making treatment development more or less challenging (44, 45). 
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1.5 Cancer immunotherapeutic approaches 
This part serves to give a brief overview of some immunotherapeutic approaches currently 
available. Immune therapy against cancer aims to enhance or reactivate the host’s immune 
system in order to recognize and control tumor progression. Several immune therapeutic 
approaches have been tested, among them monoclonal antibodies, adoptive transfer of immune 
cells, immune-checkpoint inhibitors and engineered immune cells. The use of tumor-associated 
antigens (TAA) as targets, which are native antigens overexpressed by or mutated within the 
tumor, is the most common method in cancer vaccination strategies and has been applied in 
many different cancers. Key factors in the generation of successful tumor vaccines are their 
potency to use TAA-restricted MHC class I peptides for the activation of CD8+ T cells (CTLs) 
and NK cells for tumor cell elimination (46). 
1.5.1 Cell-based therapies 
1.5.1.1 NK cell therapy 
As previously described, NK cells are able to detect and eliminate tumor cells without requiring 
previous activation signals. The Fc receptor CD16 on NK cells, can bind to the Fc portion of 
IgG to induce ADCC. Furthermore, induction of CTLs and DC maturation, which are crucial 
in tumor clearance, is highly dependent on innate signals, for example those derived from NK 
cells (47). Adoptive cell therapies using NK cells have been evaluated for both solid tumors 
and hematological malignancies. In colorectal cancer patients, an increased NK cell tumor 
infiltration was associated with a favorable prognosis, thus highlighting the significance of 
these cells in cancer immunosurveillance (48). In brief, NK cell therapeutic strategies focus 
on; i) NK cell activation, ii) hematopoietic stem cell transplantation (HSCT) (bone marrow 
replacement), or iii) adoptive transfer of NK cells. Thus, NK cell therapies have primarily been 
successful in treating hematopoietic malignancies (49). After allogeneic, T cell depleted, 
HSCT, NK cells mediate a graft-vs-tumor (GVT) effect in which transplanted NK cells 
recognize the host tumor cells as foreign and prompt tumor cell elimination. Importantly, the 
use of allogeneic NK cells did not induce graft-vs-host disease (GvHD), but selectively 
targeted the tumor cells (50, 51).  
1.5.1.2 NKT cell therapy 
iNKT cells can be activated directly by tumor cells expressing lipid antigens on the cell surface, 
which will stimulate innate and adaptive responses by the release of IL-4 and IFN-γ. Their 
activation provides secondary induction of NK cell activity by secretion of IFN-γ (1). The 
discovery that αGC could be used as a potent antigen to stimulate iNKT cell anti-tumor activity 
lead to the initiation of several clinical trials. However, repeated administration of αGC was 
unfortunately shown to induce iNKT cell anergy and little or no therapeutic effect has been 
demonstrated (14, 52-54). Tumor cells avoid recognition by the immune system via 
downregulation of CD1, whereupon they become undetectable to iNKT cells (55). In contrast 
to the anti-tumor role of iNKT cells, the opposite is true for the type II NKT cells, which 
perform immune suppression and inhibit the activity of iNKT cells (56). 
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1.5.1.3 DC therapy 
Autologous DCs cultured ex vivo have been commonly used in cancer vaccines to present 
TAA peptides mainly for activation of CD8+ T cell-mediated tumor cell killing (46). An 
advantage of using DCs is their capability to activate both CD4+ and CD8+ T cells (57). One 
of the first clinical trials using DC-based vaccines was in melanoma patients using autologous 
DCs pulsed with the MHC class I-restricted melanoma-associated antigen (MAGE)-1 peptide 
for induction of peptide-specific CTLs (58). Since then, many clinical trials using DCs have 
been performed (59, 60). Another clinical trial used the full length melanoma-associated 
antigen recognized by T cells (MART)-1-loaded onto DCs in the treatment of melanoma 
patients and identified antigen-specific CD4+ and/or CD8+ T cells in nearly half of the 
patients (61). However, the efficiency of these vaccines depends on a multitude of factors, 
primarily the activity level of the host immune system, the cancer state of the patient leading 
to immune evasion, treatment dose and the injection route. Taken together, in many cases 
these and other factors lead to poor clinical response to the vaccines (62). Furthermore, 
clinical trials using tumor lysate loaded DCs or APCs have also been tested and reported to 
induce some CD8+ T cell responses in patients with melanoma (63) and fibrosarcoma (64). 
Novel DC vaccine strategies have focused on improving cell culture conditions for the 
production of more immune-stimulatory DCs (65, 66). Importantly, an efficient DC vaccine 
requires the transport of antigens to the host immune cells for an efficient CD8+ T cell 
priming (67). 
1.5.1.4 T cell therapy 
T cell-based immunotherapies rely on the expansion of patient-derived tumor-specific T cells 
ex vivo, commonly both CD4+ and CD8+ T cells, so called adoptive T cell therapy (68). In a 
recent clinical study, adoptive transfer of tumor infiltrating lymphocytes (TILs) with peptide 
specificity for mainly TIL-3775 and TIL-3853, was used in cervical cancer patients, which 
demonstrated both antigen-specific CD4+ and CD8+ T cell responses to these peptides (69). 
However, TIL treatment specific for certain TAA has mainly been successful in melanoma 
treatment. In addition, genetically engineered T cells, chimeric antigen receptor (CAR) T 
cells have also been extensively tested in clinical trials (68). CAR T cells have antibodies 
fused to the T cell receptor which circumvent the need of tumor cell presented MHC/peptide 
complexes for T cell activation. Many clinical trials using genetically modified autologous T 
cells have been explored in the treatment of B cell malignancies, where CD19-specific CAR 
T cells have been used to target B cells (70). This treatment leads to an overall B cell depletion 
and consequently may cause severe side effects, primarily cytokine release syndrome and 
neurotoxicity. 
1.5.2 Additional therapies 
1.5.2.1 Peptide-based vaccines 
Peptide-based cancer vaccines commonly aim at CD8+, and not CD4+, T cell stimulation, 
mainly using short peptides for DC loading. Limited effects have been observed in clinical 
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studies even in the presence of adjuvants for further enhancement of the immune response. 
Although these vaccine strategies were shown promising in mouse models, not all patients 
express human leukocyte antigen (HLA) molecules that are able to present the TAA peptides, 
thus excluding vaccination as an option for certain patients. Another alternative to overcome 
the limited effect by using solely MHC class I-restricted peptides is the use of long synthetic 
peptides that are able to stimulate both CD4+ and CD8+ T cells (46). Notably, it has been 
shown that long synthetic peptides, compared to whole proteins, are more efficiently 
processed by DCs, leading to a more efficient T cell stimulation (71). 
1.5.2.2 Antibody-based therapeutics 
The mechanism of action for monoclonal antibody-based tumor cell killing is mainly by 
induction of ADCC or complement-dependent cytotoxicity (CDC) (72). Antibodies for 
immunotherapy have been established and approved; the first ones being the anti-CD20 
antibody used in the treatment of non-Hodgkin lymphoma (73, 74) and anti-HER2/neu 
antibody for the treatment of breast cancer (75). Another antibody-based therapeutic approach 
is checkpoint blockade therapies, such as anti-CTLA-4 and anti-PD-1 antibodies, for releasing 
the immunological brake induced by the TME, with the aim to reactivate immune cells in the 
fight against the tumor (76, 77). Notably, the full mechanistic effects of these treatments are 
not yet clarified, but both tumor cells and immune cells can express these molecules, and be 
directly targeted by the treatment. It has been demonstrated that anti-CTLA-4 treatment 
enhances effector CD4+ T cell activity and downregulates Treg function (78, 79). Similarly, 
anti-PD-1 induces effector T cells, NK cells, and reduces Treg-induced immune suppression 
(78, 80). Both anti-PD-1 and anti-CTLA-4 have been efficient in cancer treatment and were 
recently approved by the US Food and Drug Administration (FDA). Unfortunately, checkpoint 
blockade often cause systemic adverse effects, such as inflammation, as they disrupt normal 
immune homeostasis. Moreover, long-term effect of such treatments are still not known (76). 
Another restrictive aspect of checkpoint inhibitors is that the tumor cells quickly adapt to the 
environment by downregulating the targeted markers, which decrease treatment efficacy. 
Adaptive therapies are considered costly, time consuming and are restricted to some 
malignancies. Importantly, combination therapies merging several of the above-mentioned 
strategies are currently being tested in the treatment of cancer. One such strategy was recently 
tested in a clinical phase I study in melanoma patients, where TILs were infused together with 
DCs loaded with tumor lysate. The study demonstrated safety, albeit with limited tumor 
regression probably related to the low number of participants (81). Also, a combination of 
tumor cells and DC hybrids showed induction of CTL and tumor regression in renal cell 
carcinoma patients (82). Furthermore, allogeneic pro-inflammatory DCs have been 
intratumorally injected in patients with renal cell carcinoma and were shown to induce an anti-
tumor response (83). In conclusion, passive immunotherapies based on antibodies or T cells 
mainly induce weak immune responses and restricted memory T cell formation and therefore 
provide a limited vaccine effect. Instead, active therapies for example mediated by DCs, which 
  11 
drives both effector and memory T cell formation would have the potential to improve the 
vaccine properties. 
1.6 Extracellular vesicles 
1.6.1 Introduction to extracellular vesicles 
All cells release extracellular vesicles (EVs), which can be found in all body fluids. They are 
generally subdivided into apoptotic bodies, microvesicles and exosomes, all of which are 
suggested to have diverse functions (84). EVs constitute a highly heterogeneous group and are 
commonly classified based on cellular origin, size and their different properties (85). The 
nomenclature is still not consistent in the vesicle field, and the functional aspects related to 
vesicle size are currently under investigation (86). When EVs, primarily exosomes, were 
discovered they were considered as a way for cells to remove unwanted material (87, 88). 
Today, EV research is a field under continuous expansion and some of these aspects will be 
further addressed in this thesis. 
1.6.2 The discovery of extracellular vesicles 
Extracellular vesicle release was first described for membrane vesicles of two sizes, a larger 
and a smaller population both carrying ecto-enzymes (89). This was followed by other studies 
of EVs budding off from the plasma membrane. They were also, early on, described as 
released secretory granules present in semen (90) and human platelet microparticles found in 
serum and plasma (91). Small vesicles are formed in a structured way in the multivesicular 
bodies (MVBs) and are subsequently secreted as vesicles (exosomes) to the extracellular 
environment by fusion of the MVB and the plasma membrane (88, 92). The term “exosomes” 
was first used for their identification during the process of transferrin receptor removal by 
maturating reticulocytes (93). The discovery of exosome secretion by immune cells; B cells 
(94), T cells (95) and DCs (96) further raised the interest to study their role in the immune 
system. 
1.6.3 Exosome formation and secretion 
All cell types secrete exosomes (97) and they have been found in different body fluids, for 
instance, breast milk (98), sputum (99), urine (100) and plasma (101). Exosome formation is 
initiated by a plasma membrane invagination and the endocytosis of cell surface proteins, 
which will lead to the formation of early endosomes (figure 2). Proteins can then either be 
recycled back to the cell surface or the early endosome can mature into late endosomes (102), 
which will further develop into MVBs (103). Exosomes are formed by an inward budding of 
the endosomal membrane (103). Hereafter, the MVBs may either be degraded by the lysosome 
or they can fuse with the plasma membrane to release the exosomes to the extracellular 
environment (31). The generation of exosomes requires packaging of proteins, lipids and other 
cargo, in a process guided by the endosomal sorting complex responsible for transport 
(ESCRT), which includes the ubiquitination, i.e. tagging of proteins for degradation (104). The 
ESCRT complex involves several ESCRT proteins, specifically ESCRT-0, ESCRT-I, ESCRT-
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II, ESCRT-III and VSP4, which are responsible for the stepwise sorting of ubiquitylated 
proteins into intraluminal vesicles (105). MVBs of two different types may occur, those that 
are tetraspanin- and cholesterol-enriched, and those that are low in cholesterol yet high in 
lysobisphosphatidic acid (102). In addition, the formation of CD63 loaded exosomes was also 
shown to occur in an ESCRT-independent pathway, when the ESCRT-complex was silenced 
(106), a process that instead rely on ceramide presence (85, 107). Furthermore, proteins of the 
Rab family, small Ras-like GTPases, are important for intracellular transport pathways within 
the cells and the release of exosomes, which was demonstrated by the generation of certain Rab 
protein knock-outs. Importantly, the loss of Rab27a and Rab27b (108) and Rab7 (109) 
expression strongly reduced the release of exosomes. The Rab proteins are not continuously 
expressed, suggesting that different cell types develop their own vesicle release pattern (85). 
For exosome release, the MVBs fuse with the plasma membrane, a process suggested to be 
mediated by soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 
proteins (85). Exosomes derive from the endosomal pathway and are generally considered to 
be 30-150 nm in diameter and float at a density of 1.13-1.19 g/ml. Microvesicles, on the other 
hand, are roughly 100-1000 nm in size (110) and depending on definition, float at a density 
around 1.12-1.21 g/ml (111). They bud off directly from the cell surface, a process that was 
first described to occur in platelets (112), and early described upon neutrophil stimulation 
(113). Further, apoptotic bodies, roughly 1000-5000 nm sized vesicles, are generated when 
cells undergo programmed cell death as an organized form of packing their cellular 
compartments for elimination (19, 114, 115). 
 
Figure 2. Exosome biogenesis starts by endocytosis of proteins at the plasma membrane and the formation of 
early endosomes. During late endosome maturation, intraluminal vesicles are formed by inward budding of the 
limiting membrane, which give rise to MVBs that can fuse with the lysosome for degradation or be transported 
to the plasma membrane for fusion and exosome release. Microvesicles on the other hand directly bud off from 
the plasma membrane. 
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1.6.4 Exosome composition 
Exosomes are built up by a lipid bilayer containing cholesterol, phosphatidylserine (PS) and 
sphingomyelin (116). They also contain a large diversity of proteins, many of which are 
common to the majority of exosomes (117). Such proteins are those involved in the MVB 
formation of exosomes, for example the ESCRT proteins. Others are related to the membrane 
transport and lastly some of them are important for the fusion with the plasma membrane, as 
described for the Rab proteins (108, 118). Exosomes are, compared to the cell membrane, 
commonly enriched in tetraspanins, such as CD9, CD63 and CD81, a group of proteins 
involved in exosome formation and protein sorting onto exosomes (117, 119). Moreover, 
tetraspanins are also central in the regulation of ESCRT-independent vesicle formation (85). 
Tetraspanins are transmembrane proteins involved in various biological functions, e.g. cell 
adhesion and membrane fusion, but besides being present on exosomes they are also 
expressed on other vesicle subtypes (120). Different vesicle populations were compared for 
their tetraspanin content, which revealed that CD9, CD63 and CD81 positive vesicles 
represented exosomes, while solely CD9 was present on plasma membrane associated 
vesicles, i.e. microvesicles (111). In addition, ESCRT proteins and some of their associated 
proteins Alix and VSP4B can also be found on exosomes. Also, Syndecan was shown to 
recruit Alix and Syntenin and support their essential interaction for intraluminal budding of 
the endosomal membrane, a function that is blocked in the absence of Rab7 (109). 
Furthermore, exosomes contain Tsg101 and Annexin, proteins that are involved in the 
docking of MVBs with the plasma membrane to secrete the exosomes (97). Exosomes are 
also enriched in heat shock proteins (Hsp), e.g. Hsp70 and Hsp90 (117). In general, exosomal 
protein content is believed to be reflective of their cell of origin, on the health status of the 
cell and the stimuli that induced exosome secretion (85) (figure 3). For example, exosomes 
from APCs, e.g. DC-derived exosomes (DEX), carry MHC class II molecules and other DC 
related markers such as costimulatory molecules (96). Interestingly, exosomes also carry 
messenger RNA (mRNA) and micro RNA (miRNA) located inside the exosomes safely 
protected from degradation by RNases for transportation to the recipient cell (121). The RNA 
is believed to be packed into the exosomes in a strictly regulated manner (122). Mainly small 
RNA, with a low molecular weight, can be detected in exosomes. In contrast, ribosomal 
RNAs (rRNA) (18S and 28S) are generally absent in exosomes (123). However, it was 
recently shown that some exosome fractions may as well contain 18S and 28S rRNA subunits 
(124), thus the exosomal RNA content observed might be influenced by the isolation 
technique used and purity of the vesicle preparations. Interestingly, exosomal RNA content 
is not entirely reflecting their cell of origin, which points to a selective loading of certain 
RNA into the exosomes (121, 122, 125). 
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Figure 3. Illustration of the molecular composition of dendritic cell-derived exosomes carrying surface markers, 
e.g. tetraspanins, costimulatory molecules, MHC class I and class II and also mRNA, miRNA and other proteins 
involved in vesicle formation. 
1.6.5 Exosome isolation and characterization 
1.6.5.1 Exosome isolation methods 
There are several ways to isolate extracellular vesicles from cell supernatant and biological 
fluids. The choice of isolation method depends on the amount of available material, 
experimental design, type of exosomes, their origin (cell cultures or body fluid) and the 
specific research question (126, 127). One of the most commonly used methods for exosome 
isolation is differential centrifugation (93, 128), where vesicles of different size and density 
are pelleted based on centrifugal force. In brief, cells and debris are discarded at a 
centrifugation force of 300x g, followed by removal of large protein aggregates and apoptotic 
bodies at 3,000x g. Thereafter, larger vesicles like microvesicles are isolated at around 
10,000x g, followed by exosome isolation at around 100,000x g, even though protocols might 
vary slightly. Size restricted filtration may be used to remove larger particles between the 
10,000x g and the 100,000x g spin. In addition, the samples may be further purified using a 
density gradient, e.g. sucrose gradient or iodixanol (111, 128). Moreover, exosome isolation 
kits can be used for quick vesicle isolation, such as precipitation, bead-based or 
immunoaffinity-based methods. However, unknown isolation buffers and conditions might 
alter exosomal characteristics by these procedures, which may affect downstream 
applications. In addition, the precipitation will co-pellet all vesicles, without selecting diverse 
vesicle populations based on size. Another commonly used isolation method is size-exclusion 
chromatography (SEC). Vesicles interacts with beads in a column for separation based on 
size and not on molecular weight, providing a gentle separation leaving the exosomes 
unaffected (129). Importantly, the isolation method of choice is important for further analysis 
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of the vesicles, as they all have potentials and limitations, and thus needs to be carefully 
considered with the specific research question in mind. 
1.6.5.2 Exosome visualization and characterization 
Several methods can be applied for exosomal visualization. One of them is transmission 
electron microscopy (TEM). By using TEM, exosomes were first described to have a cup 
shaped morphology (128). However, this appearance was likely caused by sample 
preparation since later on using cryo-EM, for preserved exosomal shape, exosomes were 
described to have a round appearance (130). Of note, ultracentrifugation may affect the size 
and appearance of exosomes, due to vesicle collapse or fusion when high force is applied. 
Highly specialized flow cytometers can visualize antibody targeted exosomal surface 
proteins directly although often they lack the resolution required. Consequently, currently the 
most common way to characterize exosomes by flow cytometry, is based on beads coated 
with antibodies to capture exosomes. However, antibody-based capturing will select a 
subpopulation of vesicles positive for the particular marker for phenotyping, which can be 
avoided by the use of uncoated beads. A commonly used method to estimate the size 
distribution and concentration of vesicles is nanoparticle tracking analysis (NTA) (131), 
although it has been questioned whether NTA is robust enough to determine the vesicle 
concentration and give reproducible results. Importantly, NTA works better for mono-
dispersed rather than poly-dispersed samples (132, 133). Other commonly applied methods 
for exosome phenotyping are ELISA for surface markers and western blot for proteins 
enriched inside of exosomes, such as Alix, Tsg101 and Hsp70 (117). The RNA profile of 
exosomes can be studied by the use of the chip-based capillary electrophoresis (Bioanalyzer), 
and individual RNAs can be analyzed by RNA sequencing, RNA microarrays and 
polymerase chain reaction (PCR). The exosomal RNA profile is dissimilar to cellular RNA 
and also the RNA profiles might differ depending on the vesicle type (121, 134). Moreover, 
the exosomal RNA isolation method of choice has been shown to influence the yield and 
quality of the extracted RNA (135). Taken together, applying several methods is 
recommended for exosome characterization however the sample amounts available often 
restricts the use of multiple methods. 
1.6.6 Exosomes in cell-to-cell communication  
Exosomes are intercellular messengers able to transport information over long distances to be 
received by distant cells (136). There are both specific and non-specific ways of exosomal 
binding and uptake by cells. The non-specific, clathrin-independent, uptake is achieved by 
macropinocytosis, phagocytosis or membrane fusion. Specific exosomal interaction with the 
plasma membrane surface receptors may induce intracellular signaling or clathrin-mediated, 
i.e. receptor-mediated endocytosis, binding and internalization via integrins (137), tetraspanins 
(138) and proteoglycans (139). The target specificity is controlled by the surface markers 
expressed on the exosome and the recipient cell (85, 116). Many examples of exosome and cell 
interactions can be found in the literature. For example, DC-derived exosomes carry the 
intercellular adhesion molecule (ICAM)-1 which is important for the interaction and activation 
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of T cells via integrin leukocyte function-associated antigen (LFA)-1 mediated exosomal 
capture (140). Moreover, LFA-1 expression on activated CD4+ T cells facilitate the recruitment 
of MHC class II positive DC-derived exosomes (141). Exosomes can be transported through 
the blood stream and captured by marginal zone phagocytes in the spleen, by Kupffer cells in 
the liver or by macrophages in the lungs (31). CD169 is an important molecule for exosomal 
capturing in spleen and lymph nodes in mice, and induction of antigen-specific immune 
responses towards the exosomal carried antigens (142). CD169+ macrophages in the lymph 
nodes act as tumor suppressors by capturing TEX and inhibit exosome promoted tumor 
progression (143). Organ selectivity has been further confirmed for cancer-derived exosomes, 
where target specificity to certain organs have been observed in vivo, termed organotropism, 
which is related to specific integrins present on the exosomes (144). Cancer-derived exosomes 
are also dependent on heparin sulfate proteoglycans for their uptake and function (139). A 
previous investigation of the exosomal fate in vivo presented that DC- and B cell-derived 
exosomes were complement resistant, which would suggest that they can provide a long-term 
effect (145). Recent studies propose a shorter exosome half-life in circulation although 
exosomes were still detectable in the spleen after being captured by MMM in the marginal zone 
(138, 142, 146). Furthermore, upon uptake the information carried by the exosomes, primarily 
proteins and RNA, are further processed by the recipient cell (147). In addition to delivering 
antigens to recipient cells, exosomes carry multiple signals that promote activation of host cells 
to provide an adjuvant effect (31). For example, glioblastoma-derived exosomes carrying 
functional mRNA have been shown to promote tumor growth in vitro (125). Exosomes may 
also deliver functional miRNA to recipient cells in vitro (147, 148), demonstrating that they 
can transfer information and be explored for therapeutic delivery of material. Moreover, 
exosomes can be loaded for transport of small interfering (siRNA), which can be delivered to 
tumor cells in order to knock down genes in vitro and in vivo. Also, exosomes loaded with 
mRNA have been successively transported to tumor cells. This suggests that exosomes 
plausibly can be used in RNA-based gene therapy in the future (149). 
1.7 Exosomes and the immune system 
1.7.1 Immune-stimulatory function of exosomes 
The first study identifying a connection between exosomes and the immune system was the 
observation that B cell-derived exosomes carried MHC class II molecules that could present 
peptides to CD4+ T cells and induce an antigen-specific response in vitro (94, 150). This 
motivated further investigations of exosomes and their role in immune stimulation. Exosomes 
originating from APCs carried MHC class I and class II molecules and were therefore potential 
inducers of CD8+ and CD4+ T cell responses, respectively (151, 152). For example, DEX 
presented immune-stimulatory properties by the activation of CD4+ T cells in vitro (96), and 
successfully induced tumor-specific CD8+ T cell responses in vivo (31). It has been shown 
that when exosomes interacted directly with T cells they induced a low immune-stimulatory 
effect, whereas when incubated with DCs they prompted efficient T cell stimulation (153). 
Thus, activation of DCs to prime T cell responses have been suggested as the major 
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mechanism in vivo (154). In contrast, direct T cell stimulation by exosomes was mainly 
observed when exosomes encountered CD4+ T cells in vitro (155). Importantly, DCs were 
shown crucial for inducing immune activation in response to exosomes in vivo (156). 
Moreover, DEX efficiently transfer MHC class I-peptide complexes to DCs for the priming 
of CD8+ T cell responses in vitro and in vivo (157). For immune activation, exosomes may 
be engulfed by DCs and the exosomal MHC/peptide complexes transferred “cross-dressed” 
to the DC surface, another possibility would be that exosomes stay attached to the DC surface 
to interact with the T cell directly (31, 158). MHC class II deficient DCs were able to 
stimulate antigen-specific CD4+ T cell in vivo, suggesting the transfer of MHC complexes 
from exosomes to the DC surface for immune activation (152). After exosome internalization, 
the exosomal MHC/peptide complex can be recycled (151), or degraded by the DC and the 
peptides can be recycled (159). In addition, antigen-loaded exosomes need B cells to generate 
CD4+ and CD8+ T cell responses in vivo (160). Moreover, an immune-stimulatory effect by 
macrophage-derived exosomes have been observed in vivo, they specifically target the lymph 
nodes where they promote a pro-inflammatory cytokine environment (161). Studies have also 
demonstrated that tumor-derived exosomes (TEX) can activate immune cells in vitro by 
carrying MHC class I molecules and heat shock proteins, and that they may also provide an 
anti-tumor effect in vivo (162). In support of this, TEX loaded DCs injected in tumor bearing 
mice induced more antigen-specific CD4+ T cells, stronger anti-tumor response and prolonged 
survival compared to tumor-lysate loaded exosomes (163). 
1.7.2 Immune inhibitory function of exosomes  
Exosomal function is dependent on their cellular origin, thus many exosomes have shown an 
immune inhibitory capacity, e.g. tumor-, placenta-, gut- and stem cell-derived exosomes. 
Notably, the route of administration in different experimental models also affects whether 
exosomes will induce an activating or inhibitory immune response. For example, immune 
suppressive functions have been described for intestinal epithelial cell line-derived exosomes 
“tolerosomes” exposed to OVA and from serum-derived exosomes in mice after oral antigen 
administration (164). Upon oral administration of OVA, tolerosomes were able to prevent 
allergic sensitization in a mouse model for asthma and these mice presented higher levels of 
Tregs and lower levels of IgE (165). Also, bronchoalveolar lavage fluid (BALf)-derived 
exosomes from mice exposed to the pollen allergen (Ole e 1) showed immune suppressive 
functions such as the inhibition of IgE responses and increased TGF-β production and 
prevented allergic sensitization in the recipient mice (166). Plasma-derived exosomes from 
mice enriched in MHC class II molecules and FasL displayed an antigen-dependent immune 
suppressive function (149). Furthermore, placenta-derived exosomes have an immune 
suppressive role during pregnancy (167), partly mediated through the expression of FasL and 
TRAIL on the exosomes important for induction of apoptosis of activated immune cells for 
maintaining immune suppression (168). Interestingly, placenta-derived exosomes have been 
shown elevated in plasma of mothers that deliver at full term, as compared to those that 
deliver pre-term indicating a pregnancy protecting effect of these exosomes (169). Moreover, 
tumor cell line secreted exosomes, may also induce immune suppression and contribute to 
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tumor progression and metastasis (31, 170). Tumor exosomes carry tumor-associated 
antigens and immune inhibitory markers, such as FasL, TRAIL and PD-L1 (171). Notably, 
it has been shown in co-culture experiments that TEX suppress the effector CD8+ T cells 
(172, 173), and promote expansion of Tregs, further supporting an immune inhibitory 
environment (174). Not only T cells are inhibited by TEX co-culturing, also other immune 
cells, e.g. monocytes, B cells, NK cells and DCs respond to the immune suppressive signals 
expressed by TEX. For example, TEX prevented monocyte differentiation and induced TGF-
β expression by DCs for further immune suppression (171). Notably, TEX derived from 
metastatic cell lines promote more metastasis compared to exosomes from non-metastatic 
cell lines, and they also stimulate a pro-metastatic phenotype of bone marrow progenitors 
(170). In addition, injection of the tumor cell line E.G7-derived exosomes expressing OVA 
was non-immunogenic in vivo (156), further supporting an immune evading capacity of 
tumor exosomes.  
1.8 Exosomes in cancer immunotherapy 
Since exosomes were first shown to carry functional MHC/peptide complexes, the use of 
DEX has evolved as a promising approach in immunotherapy. The first attempt to use a cell-
free approach in cancer treatment was successfully performed by the use of DEX in a mouse 
melanoma model (96). This led to the start of two phase I clinical trials using DEX in 
melanoma (175) and in non-small cell lung cancer (176). The main conclusions from these 
two clinical studies were that it was possible with large scale production of DEX and that 
they were safe to be administered in humans. However, these studies failed to show a 
sufficient upregulation of CTLs in the patients, which probably depended on the late stage 
tumor status and also the use of immature DCs for exosome collection. In a recent phase II 
clinical trial, using IFN-γ matured DEX loaded with MHC class I and class II tumor peptides, 
DEX were shown able to induce NK cells while negligible T cell responses were observed 
in patients with lung cancer (177). DEX expressing NKG2D ligands have been shown to 
activate NK cells by binding NKG2D ex vivo and in vivo, and also to improve metastatic 
control via NK1.1+ cells (178). Notably, the addition of LPS or IFN-γ to the DC culture 
before exosomal isolation improved their immunogenic capacity by upregulation of 
exosomal costimulatory markers (140, 150). The use of peptide-loaded exosomes was not 
sufficient to trigger strong anti-tumor immune responses in the human clinical setting and 
another limitation was the use of an autologous system. It has been suggested that an 
allogenic system would serve as an alternative without causing severe side effects. Thus, 
allogeneic exosomes have been shown to deliver antigens, stimulate immune cells and 
suppress tumor growth and are therefore suggested as a potent cell-free cancer vaccine (179). 
Importantly, not only DCs are important for a good exosome-based vaccine response, also B 
cells are crucial for mounting CD4+ and CD8+ T cell responses as previously demonstrated 
(160, 180). This propose the use of whole antigens on exosomes for therapy and not solely 
loading of T cell peptides for immune activation. Further suggesting that allogeneic 
exosomes may be used, since the direct exosome and T cell receptor interactions via 
MHC/peptide complexes are negligible in vivo.  
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Contradictive data propose a dual function of TEX, as both inhibitory and stimulatory 
functions have been described. Their role in the immune therapeutic setting was suggested to 
be defined by the TME and the cells targeted by the TEX treatment (171). Importantly, TEX 
naturally transport tumor antigens that can be taken up by DCs and be further presented to 
CTLs to induce an anti-tumor specific immune response. Interestingly, both syngeneic and 
allogeneic TEX have been confirmed equally potent in tumor eradication (161). The first 
phase I clinical trial combining tumor-derived exosomes with granulocyte-macrophage 
colony-stimulating factor (GM-CSF) was performed in patients with colon cancer, 
unfortunately tumor-specific CD8+ T cell responses were only detected in some patients 
(181). Importantly, TEX has been shown less efficient in induction of CD8+ T cell responses 
compared to DEX (156).  
Other stimuli may be complemented to the exosomes to further potentiate their immune-
stimulatory function. The addition of the NKT ligand α-galactosylceramide to the DEX 
enhanced the immune response by the engagement of invariant iNKT cells, which also 
inhibited tumor progression in mice (182). DEX co-administered with the TLR9 ligand CpG-
ODN also successfully boosted the anti-tumor immune response in vivo (183).  
Mesenchymal stem cell (MSC)-derived exosomes have mainly been tested in clinical trials 
for GvHD and chronic kidney disease due to their immune suppressive nature (184, 185). 
MSC-derived exosomes may plausibly also provide an anti-tumor therapeutic alternative. 
However, the role of MSC-derived exosomes in cancer treatment needs to be further explored 
(186). So far, the exosomal induced immune-stimulatory effect on cells and their ability to 
induce tumor regression observed by diverse sources of exosomes in mouse models have 
unfortunately not corresponded well with the observations made in clinical trials. 
1.9 Exosomes in disease diagnostics 
Exosomes in body fluids reflect their cell or tissue of origin and selective loading of proteins 
to exosomes suggests that they may serve as potential noninvasive biomarkers. Altered 
exosome quantities and their cargo have been associated with a wide range of diseases; 
sarcoidosis (187), cancer (100, 188), Alzheimer’s disease (189), cardiac disease (190), and 
asthma (99, 191), and thus exosomes might serve as easily accessible “liquid biopsies” for 
biomarkers or prognostic markers of disease (162, 192, 193).  
Several studies investigating the protein content of exosomes from diverse sources using 
different techniques have been performed and numerous proteins have been associated with 
cancer diagnosis and prognosis (98, 144, 194-196). For example, melanoma-derived exosomes 
present a “melanoma profile”, by the transport of proteins, such as MET, TYRP2 and Hsp70 
important for metastasis formation, demonstrating their potential as disease markers (170). In 
addition, serum-derived vesicles from glioblastoma patients contain epidermal growth factor 
receptor (EGFR) to a higher extent compared to controls, thus potentially indicating their 
diagnostic capability (125). From a biomarker perspective, finding highly specific early 
detectable markers are crucial. One such protein is the glypican-1 identified as an early 
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pancreatic cancer marker in human plasma-derived exosomes, which also correlated closely to 
tumor burden and could furthermore be linked to prognosis (197). Notably, proteomic 
approaches to find exosome biomarkers have been extensively investigated (116, 198, 199). 
Taken together, they all suggest that exosomal protein content can be investigated in a 
biomarker perspective. In contrast, the lipid profile of exosomes has recently become more 
explored using sensitive mass-spectrometry (200, 201). 
Exosomes have also been shown to transport tumor-derived mRNA and miRNA, which also 
increased their interest from a biomarker perspective. Since then, the exosomal biomarker field 
has largely focused the attention on exploring the correlation of exosomal RNA and disease 
diagnosis (170, 202). For example, the levels of selected miRNAs observed in ovarian cancer-
derived exosomes correlated to the miRNA profile of the tumor cells. Importantly, these 
miRNAs were uniquely expressed in the TEX and absent in healthy ovarian tissue suggesting 
their potential as biomarkers (203). In another study, serum-derived exosomes from 
glioblastoma patients presented an overall increase in total RNA content in comparison to 
healthy individuals and a reduction in some specific rRNAs which are objects for further 
investigations as biomarkers for glioblastoma (204). 
In conclusion, sensitive methods feasible for high-throughput analyses are necessary for 
exosomal investigation of disease diagnostic and prognostic markers. New screening 
methods are under development and collection of data in comprehensive data bases will 
further contribute to the potential to reveal disease patterns for predicting prognosis. At 
present, several clinical trials investigating exosomes as biomarkers for diverse cancers are 
ongoing and the outcomes of these trials remain to be revealed. Hopefully, improved disease 
diagnostics will be available in the near future, as the screening possibilities will also provide 
more individualized treatment strategies. 
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2 THESIS AIMS 
The main focus of this thesis was to study exosome-induced immune responses in vivo and 
how to improve their stimulatory capacity for immunotherapy. In addition, this thesis explored 
a novel technology for identifying protein profiles in human body fluid-derived exosomes for 
improving the applicability of exosomes for diagnostics purposes. 
Study I 
This study aimed to investigate the role of MHC class I molecules on exosomes to identify 
whether MHC/peptide complexes are required on the surface of exosomes to trigger antigen-
specific CD8+ T cell immune activation in vivo and to explore the application of allogeneic 
exosomes in cancer immunotherapy. 
Study II 
The aim of this study was to, as a follow-up to study I, evaluate the ability of allogeneic 
exosomes to activate an antigen-specific immune response and examine the effect of repeated 
injections of allogeneic exosomes on the development of immune memory and to further 
explore their immune therapeutic potential in a tumor model. 
Study III 
The aim was to explore the use of lyophilization as a novel strategy for antigen and adjuvant 
loading of macrophage cell line RAW 264.7-derived exosomes and to test their immune-
stimulatory potential and their capacity to reduce tumor progression in vivo. 
Study IV 
This study aimed to examine the proximity extension assay (PEA) as a means of identifying 
exosomal proteins in small sample volumes and to distinguish differential protein patterns 
between cell lines and their corresponding exosomes, with the purpose to investigate the 
feasibility of using PEA as a diagnostic tool. 
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3 METHODOLOGY 
All methods used in this thesis are described in detail in the individual studies. Thus, this part 
serves to provide a broader overview of the methods applied and also to identify 
methodological considerations in the exosome field and the studies performed. Although, there 
are limitations to the individual methods, they serve as a complement to each other and 
contributes to the final understanding and interpretation of the results. 
3.1 Mice 
All animal experiments were approved by the local ethics committees. In study I-III, C57Bl/6 
and BALB/c mice were used. MHC class I-/- mice (lacking both H2Kb and H2Db genes) were 
kindly donated by Klas Kärre (Karolinska Institutet) and OT-I/Rag2-/- mice with TCR specific 
for OVASIINFEKL peptides, both on a C57Bl/6 background, respectively were bred at Karolinska 
Institutet, MTC animal facility. The experiments are explained in detail in the individual studies 
performed and summarized in figure 4. In brief, to examine immune stimulation in vivo, 
exosomes were injected intravenously (i.v.) (study I-II) or intraperitoneally (i.p.) (study III). 
Notably, the injection routes are suggested to affect the fate of the exosomes, and exosomes 
injected i.v. are systemically distributed and predominantly target the liver, as compared to i.p. 
injected exosomes, which largely interact locally with tissue resident cells. Consequently, the 
injection route of choice should be considered as it will plausibly affect the outcome of the 
study. Therefore, additional studies where injection routes are compared side by side are 
desired. Not only the injection route will affect the distribution, also exosomes of different 
sources carry adhesion molecules that will direct them to certain target cells and organs. 
 
Figure 4. Schematic overview of the exosome immunization schedules in the different studies I-III. 
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3.2 Tumor models 
In the B16-OVA F1 melanoma model (study I), 30,000 or 200,000 tumor cells were injected 
subcutaneously (s.c.) in female mice for tumor establishment. For the B16m-OVA F1 
melanoma model (study II), 50,000 tumor cells were injected s.c. in female mice and tumor 
development was confirmed. In both study I and II, bone marrow-derived dendritic cells 
(BMDC)-derived exosomes were injected i.v. as a therapeutic treatment model to prolong 
survival, and the tumor growth was followed until a tumor size of 1000 mm3 was reached. In 
the B16-OVA F10 melanoma model (study III), female mice were injected s.c. with 1x106 
tumor cells. This model was used as an immunotherapeutic approach and exosomes were 
injected in mice with established tumors. In the E.G7-OVA thymoma model (study III), male 
mice were injected s.c. with 5x106 tumor cells. This model was used to challenge mice that had 
been pre-immunized with exosomes to evaluate if they can be used as a protective cancer 
vaccine. In study III, the tumor growth was followed and the experiments were terminated day 
17 or day 21 for the B16-OVA and at a tumor size of 4000 mm3 for the E.G7-OVA (figure 5). 
Of note, in study III, RAW 264.7-derived exosomes were injected i.p. in both the B16-OVA 
and the E.G7-OVA model. Taken together, all tumor models were used with an explorative 
purpose to find therapeutic strategies using exosomes which can also be applied on other tumor 
types. 
 
Figure 5. Schematic overview of the exosome immunization schedules in the tumor models in the different studies 
I-III. 
3.3 Primary bone marrow-derived dendritic cell cultures 
For the generation of exosomes (study I and II), primary BMDCs were cultured from C57Bl/6, 
MHC class I-/- or BALB/c mice, respectively. The culture medium was supplemented with 
recombinant IL-4 and GM-CSF containing culture medium generated from A8653/X63 clone, 
a kind gift from Mattias Svensson (Karolinska Institutet), for stimulating DC differentiation. 
On day 6, 300 μg/ml OVA and, when required, 100 ng/ml αGC was additionally added to the 
cultures followed by an overnight incubation. On day 7, cell culture medium containing 
exosome-depleted fetal calf serum (FCS) was supplemented with LPS for DC maturation, as 
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LPS is essential for BMDC secretion of immune-stimulatory exosomes. After 48 h in culture, 
the supernatant was collected for exosome isolation. 
3.4 Cell cultures 
The murine macrophage cell line RAW 264.7 was used to generate cell culture supernatant 
containing exosomes (study III). This cell line was selected as their exosomes have been 
demonstrated less immunogenic compared to DC-derived or tumor cell-derived exosomes. 
Therefore, their function as delivery tools of OVA, CpG-ODN and αGC could be solely studied 
without interference of an immune stimulation generated by the vesicles themselves. In study 
IV, various cell lines were used for the assessment of the PEA on protein content of cells and 
their corresponding exosomes. All cell lines used were cultured according to the supplier’s 
instructions.  
3.5 Healthy human subjects 
In study IV, sample collection was performed from healthy volunteers. Breast milk from non-
allergic mothers was collected at Karolinska Institutet and processed directly or stored at 4°C 
and handled within 12 hours of sampling. Seminal fluid was collected at Uppsala University 
Hospital. The study was approved by local ethics committees and informed consent was 
obtained from all donors. 
3.6 Exosome isolation 
Throughout the studies presented in this thesis differential centrifugation was applied for 
exosome isolation. Depending on the exosome source such as cell culture supernatant or human 
body fluid the protocols were slightly modified for optimization of exosomal purity and yield. 
In some protocols, additional purification using sucrose gradient was applied (study IV). In 
brief, when working with human body fluids (study IV), these samples contain immune cells, 
proteins and lipids. For a successful exosome isolation, additional sample dilutions prior to 
vesicle isolation were required, followed by inclusion of further washing steps in order to 
remove contaminations from the vesicle preparations. In study IV, density gradient purification 
was not applied on the milk exosome preparations as this would potentially reduce the sample 
yield. However, this additional purification step will be considered in future studies when milk 
exosomes are used. For isolation of prostate-derived exosomes “prostasomes”, the sample 
purification protocol had been carefully optimized previously and included sucrose gradient 
purification, as described in study IV. For cell line-derived exosomes, the isolation protocols 
found in the literature might slightly differ. In the present study, all cell line-derived exosomes 
were isolated in a standardized way. Cell culture supernatants are less likely to have 
contaminating proteins, other than the FCS supplemented to the culture medium, which were 
excluded before final incubation and exosome isolation. Therefore, additional washing steps 
were not considered to be required. In brief, common for all exosome isolation protocols used 
here are the initiation by removal of cells and cell debris. When applicable, samples were 
filtered through a particle size restricted filter to remove larger vesicles, followed by 
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ultracentrifugation for exosome isolation and subsequently samples were stored at -80°C until 
further use. Ultracentrifugation has been questioned due to the unselective isolation and co-
pelleting of contaminants as the force applied would concentrate all particles heavy enough/of 
a particular size and weight. Moreover, there is also a risk for vesicle fusion due to the 
centrifugation force. Despite the limitations, ultracentrifugation is still considered as the 
“golden standard” technique for exosome isolation. Another limiting factor in the exosome 
field is the frequently low vesicle yield after isolation which will impact downstream 
applications such as characterization and functional studies in vitro and in vivo. Consequently, 
method optimization and controls used in the experiments always have to be carefully selected. 
3.7 Flow cytometry 
Flow cytometry was used for defining cell populations based on their surface marker 
expression. In brief, the initial incubation with Fc-block to avoid unspecific antibody binding 
was followed by addition of fluorophore conjugated antibodies. The cells were investigated 
using a flow cytometer for single cell identification of live cells, and the diverse cell populations 
were defined in the different studies (study I-III). Additional fixation and permeabilization 
steps followed by antibody incubation was applied to assess in vivo proliferation of cells using 
bromdeoxiuridin (BrdU) incorporation. In addition, intracellular production of IFN-γ (study I 
and III) was explored by incubating the cells for 4 hours ex vivo using PMA, Ionomycin and 
Brefeldin A to activate the cells, stimulate cytokine production and block intracellular protein 
transport, respectively. In addition, exosome surface markers were analyzed by flow cytometry. 
However, due to their small size of 30-150 nm in diameter, directly distinguishing true signals 
from the background is challenging using available flow cytometers. Instead, antibody 
conjugated sulfate-aldehyde latex beads were used for exosome binding to enable visualization 
of exosomal surface markers (figure 6). The purified antibody of choice varies depending on 
the exosome source to be investigated and needs to be defined for each vesicle population. 
Here, anti-CD9 conjugated beads were used for BMDC-derived exosomes (study I and II) and 
anti-CD81 conjugated beads for the RAW 264.7-derived exosomes (study III) for exosome 
characterization. Of note, the use of antibodies for the bead-based approach, thus select for the 
vesicle population comprising the marker of choice. 
 
Figure 6. Bead-based capture of exosomes for phenotyping using flow cytometry. Latex beads were coated with 
an antibody (anti-CD9 or anti-CD81) for exosome capture, followed by staining with fluorophore conjugated 
antibodies for identification of exosomal surface marker expression. 
  27 
3.8 Western blot 
Exosomal proteins are both surface exposed and found inside the vesicles. For investigation of 
intravesicular proteins, flow cytometry is not feasible since the antibodies are not able to 
penetrate the lipid membrane of the vesicles. Gentle fixation protocols used for intracellular 
markers are not capable of penetrating the rigid exosomal lipid membrane. Instead, exosomes 
are lysed using strong detergents such as RIPA buffer, for extraction of vesicle proteins 
followed by repeated vortexing and sonication for western blot identification of intravesicular 
proteins. In all studies I-IV, western blot was applied for the purpose of vesicle profiling and 
additionally to determine the amount of OVA protein carried by the vesicles (study I-III). 
Unfortunately, for exosomal protein evaluation using western blot, there are no housekeeping 
genes able to serve as internal loading controls. Here, the Turbo blot system and their pre-
casted gels is of advantage, as UV light can be applied directly on the gel for visualization of 
total protein amount loaded and thus serves as a control for total protein loading onto the gel. 
3.9 Enzyme-linked immunosorbent assay (ELISA) 
ELISA is a quick and specific antibody-based method to analyze and quantify proteins, e.g. 
secreted cytokines and antibodies in cell supernatant or serum. ELISA was used to estimate 
OVA levels on exosomes to ensure that the injected exosomal batches had similar levels of 
surface antigen (study I-III). In addition, ELISA was also used to examine antibody subclasses 
in serum of mice after exosome immunizations (study I-III). No blocking was included as the 
mouse serum contain bovine serum albumin antibodies induced by the exosomal carried FCS 
originating from the cell culture medium, which would generate a false positive signal. In study 
III, the pro-inflammatory cytokines (IL-6 and IL-12) released to the splenocyte cell culture 
medium in vitro were assessed and quantified. ELISA provides an easy platform for the 
investigation of cytokines in serum or cell culture medium, with the limitation that the cytokine 
production is transient and the kinetics require time point optimization for the different 
cytokines for assessment of cytokine expression after in vitro stimulation.  
3.10 Enzyme-linked immunospot (ELISpot) assay 
ELISpot, a sensitive method for quantification of cells releasing cytokines, was used for 
examining the IFN-γ release by splenocytes upon ex vivo restimulation (study I-III). 
Splenocytes were added to the IFN-γ capture antibody coated plates for overnight culture 
together with different stimuli; peptides for T cell stimulation (CD4 peptide: OVA323-339 and 
CD8 peptide: OVASIINFEKL), whole OVA protein for B cell stimulation or αGC for iNKT cell 
activation (study I-III). In addition, ELISpot was used for detecting antibody producing cells 
(study II) by coating the plates with anti-mouse IgG and adding splenocytes for plasma cell 
identification followed by using biotinylated OVA for detection of the antigen-specific 
antibody producing cells. This was followed by visualization and quantification of spot forming 
units (SFU)/106 cells using the iSpot FluoroSpot Reader System. The advantage with ELISpot, 
compared to cell supernatant analysis using ELISA, is that all events that occurs during the 
incubation time will be captured, which reduces the need for optimization dependent on 
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cytokine kinetics, and thus ELISpot serves as a complement to ELISA. Furthermore, the high 
sensitivity is an advantage for cytokines that are only released in small amounts. Importantly, 
cells will be evaluated for their secretion capacity in response to a specific stimuli. In contrast 
to the assessment of intracellular cytokine production using flow cytometry (previously 
described), where unspecific stimulation and blocking cytokine release affect the health status 
of the cells. Notably, ELISpot do require; i) optimization of cell numbers used in each well for 
the stimulation, and ii) adaptations of the settings for defining positive signals, SFU, using the 
plate reader. In addition, compared to intracellular cytokine staining using flow cytometry, 
ELISpot is not able to identify the cell that produced the cytokine if a mixed cell culture is used. 
For multiple cytokine analysis FluoroSpot can be applied according to the same principles as 
ELISpot, to provide information about cytokine release from a certain cell, compared to other 
multiplex assays for example Luminex which would only provide concentrations of the 
cytokines in the samples, but not reveal which cells they were secreted from, nor if the same 
cell secreted the cytokines. 
3.11 Electron microscopy 
As exosomes are nano-sized particles, high resolution microscopy is needed for visualization. 
Here, BMDC-derived exosomes from C57Bl/6 and BALB/c mice were identified by 
transmission electron microscopy (TEM) with a negative ion capture, staining the background 
and leaving the sample unaffected but visible (study II). There are different techniques 
available, e.g. TEM, scanning electron microscopy (SEM) and cryo-EM. TEM provides higher 
resolution than SEM. TEM and cryo-EM are similar with the difference that cryo-EM is 
performed at low temperatures using liquid-nitrogen, which is important for temperature 
sensitive samples and leaves the vesicles more intact, i.e. spherical. A small sample volume 
was added to a grid and stained with 5 μl 1% uranyl acetate before visualization in a Hitachi 
HT 7700 electron microscope. Images were obtained using a Veleta camera (Olympus). 
3.12 Lyophilization 
Study III comprises a novel method for external exosome loading using lyophilization. In study 
I and II indirect loading was applied to introduce antigen to the exosomes. However, indirect 
loading is not applicable on all cell lines as they might lack receptors for antigen uptake and 
consequently are unable to take up and process the antigen. As the RAW 264.7 cell line was 
not taking up OVA directly from the culture medium, the lyophilization technique (a freeze 
dry method) was applied (study III). Antigens and adjuvants were added to the exosome 
solution in phosphate-buffered saline (PBS) and they were snap-frozen followed by overnight 
lyophilization. The dried pellet was reconstituted with water and PBS to provide the 
encapsulation of antigens to the exosomes. Vesicle characterization was extensively compared 
before and after lyophilization and revealed the recovery of exosomal features. Importantly, 
the antigens and adjuvants were found co-localized with the vesicles. This method solves 
several problems; i) facilitates loading of antigens directly to exosomes, ii) allows loading of 
antigens that are not taken up by cells, iii) enables loading of innate stimuli such as CpG-ODN 
to exosomes without affecting the health status of the cells. 
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3.13 Bioanalyzer 
Exosomal RNA was isolated using the miRCURY RNA isolation kit. The total RNA profiles, 
yield and size distribution, of RAW 264.7-derived exosomes before and after lyophilization 
were assessed in study III using the chip-based capillary electrophoresis method termed 
Bioanalyzer. The RNA 6000 Pico kit for total RNA was used according to manufacturer’s 
instructions. Exosomes mainly contain small RNA, which gives them a different RNA profile 
compared to cells. 
3.14 In vitro proliferation 
OT-I/Rag2-/- mice with T cell receptors specific for the OVASIINFEKL peptide presented by the 
MHC class I molecules were used to study antigen-specific T cell proliferation in a splenocyte 
culture in vitro in response to OVA loaded exosomes presenting the CD8 peptide SIINFEKL 
on their MHC class I (study I and III). Cells were stained with the stable fluorescent staining 
carboxyfluorescein succinimidyl ester (CFSE) that will penetrate the cell membrane. 
Proliferation can be followed as the staining intensity will gradually decrease for each cell 
division. The cells were incubated for 5 days to quantify proliferation of antigen-specific T 
cells in vitro. 
3.15 Size distribution analysis of exosomes 
3.15.1 Nanoparticle tracking analysis 
To investigate the size distribution of BMDC-derived exosomes, the nanoparticle tracking 
analysis NTA was used (study I and II). Vesicle size was determined based on the rate of light 
scattering and the Brownian motion of the particles. This technique works well for mono-
dispersed compared to poly-dispersed samples, as the threshold would select the vesicle size to 
be identified and the mean vesicle size will be presented, thus making the method biased if 
vesicles of different sizes occur. The number of particles (concentration) can also be calculated 
using NTA however of different accuracy depending on the calibration of the machine and 
therefore might not be fully reliable. 
3.15.2  DLS analysis and AFM topography 
In study III, RAW 264.7-derived exosomal size distribution was evaluated using the Zetasizer 
dynamic light scattering (DLS). In DLS the laser light hits the vesicles and scatters in all 
directions. This method is limited to small particles in suspension at a low particle number and 
is therefore suitable for exosome research. DLS is a similar technique as the NTA although 
without the ability to calculate the particle concentration. In addition, the vesicle size 
distribution was further assessed by the use of atomic force microscopy (AFM) (study III). The 
high resolution microscopy will scan the surface of the dried sample by using a mechanical 
probe to create an image of the sample structure. The purpose of using DLS and AFM was to 
investigate the exosome characteristics before and after lyophilization. Of note, particle sizes 
are affecting their uptake by cells in vitro and in vivo. 
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3.16 Exosome staining for uptake studies 
Exosomes were stained using the PKH67 lipophilic membrane dye for exosome cell 
interaction/uptake evaluation in vivo (study II), as a control free dye was injected. 1h after i.v. 
injection no signal from the exosomes were detected in vivo and only MHC class II 
upregulation was observed on splenic DCs, monocytes and macrophages. Moreover, in study 
III exosomes were stained with the lipophilic dye SP-DiOC, which is highly fluorescent when 
fused with membranes and with negligible fluorescence in water, thus providing less 
background than other comparable lipid-based membrane dyes. After staining the exosomes, 
they were incubated with RAW 264.7 cells for in vitro uptake evaluation (study III). Different 
time points and also active uptake (37°C) and passive uptake (4°C) was assessed by flow 
cytometry and confocal microscopy.  
3.17 Proteomics 
The PEA technique (Olink Proteomics) was applied to investigate the feasibility to study 
exosome protein content (study IV) (figure 7). The advantage of PEA over other commonly 
used proteomic methods is the small sample volume required as a result of the increased 
sensitivity due to the PCR amplification, which is an advantage in the exosome field as sample 
amounts are often the limiting factor. The PEA method applies two DNA-conjugated 
antibodies targeting different epitopes of the same protein, which brings the DNA arms in close 
proximity and facilitate the hybridization of the DNA arms to each other, followed by 
enzymatic DNA polymerization to form a new double-stranded DNA molecule that is used as 
template for signal amplification by PCR (figure 7). Thanks to the dual target recognition, the 
reported cross-reactivity and non-specific signals are minimized. Several antibody panels were 
applied, those already available for cancer and cardiovascular diseases and those, at that time, 
under development (cell cycle, cancer and neuro-oncology), comprising 92 proteins and 
internal controls each. Several cell lines, and their corresponding purified exosomes were 
assessed to evaluate the performance of the multiplex PEA for proteome analysis of exosomes 
(study IV). Also, human body fluid-derived exosomes from healthy controls were evaluated 
for the feasibility to apply PEA on body fluid vesicles. The limitations of this technique are; i) 
similarly to other affinity-based technologies, antibody binding properties varies, not allowing 
direct comparison of protein concentrations, ii) The current protein panels are fixed, not 
allowing custom designing of panels, and iii) the platform allows relative quantification rather 
than absolute quantification of each protein. On the other hand, from a diagnostic and 
biomarker perspective when the protein of interest is already known, this method could serve 
as a possible tool to assess clinical samples due to the small sample size required. 
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Figure 7. Principle behind the PEA technique, two antibodies recognizing different epitopes on the same protein 
are incubated with the sample. Matched antibody pairs linked to unique DNA sequences will hybridize, when 
binding in close proximity this will induce extension by DNA polymerase and amplify the positive signal by PCR. 
3.18 Data analysis 
After generating the proteomic data using the PEA method (study IV) the limit of detection 
(LOD) and normalized protein expression values (NPX, expressed in log2-scale) were 
calculated. The values were then applied for data analysis using R (RStudio) after correction 
for background noise. In brief, a 2-fold cut-off of the LOD standard deviation (corresponding 
to a 95% confidence interval) was subtracted from the NPX values. The final corrected NPX 
values were used to generate the heatmaps, perform principal component analysis (PCA) and 
hierarchical clustering presented in study IV. The ComBat analysis removed specific protein 
signals present solely in cell lysates or exosomes to enable tracing of exosomes to its originating 
cell line by only comparing the protein similarities. Pearson correlation was used in 
combination with a hierarchical clustering algorithm to compare sample distances. The 
bootstrapping algorithm (pvclust package) was used to estimate statistical certainty of the 
hierarchical clustering. To allow the comparison between milk- and prostate-derived 
exosomes, the data distribution was first corrected using quantile normalization. Sample 
comparison was performed using empirical Bayes statistics to assess the differentially 
expressed proteins. 
3.19 Statistical analyses 
The statistical analyses are explained in the individual studies. In brief, all analyses were 
performed using GraphPad Prism 6.0 and presented as mean ± SEM (unless otherwise stated) 
and considered significant if p<0.05 (Study I-III). Student’s t-test or one-way ANNOVA with 
Bonferroni’s correction were used for normally distributed data. Mann-Whitney or Kruskal-
Wallis test with Dunn’s correction were applied for non-parametric data. For the tumor models, 
survival was evaluated using Kaplan-Meier survival curve and the data were analyzed using 
Mantel-Cox test. 
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4 RESULTS AND DISCUSSION 
This part serves to provide a short summary of the findings in the different projects, as they are 
discussed more detailed in the respective studies included in this thesis. In addition, a combined 
reflection on the overall findings can be found at the end of this section. 
4.1 Main findings  
4.1.1 Study I 
In this study, we found that BMDC-derived exosomes that carry the whole OVA antigen are 
able to stimulate antigen-specific CD8+ T cells both in vitro and in vivo even in the absence of 
exosomal MHC class I expression. The immune boosting effect related to engagement of iNKT 
cells achieved by the additional use of αGC on exosomes was further investigated in the context 
of exosomes lacking MHC class I. We could clearly detect the additional effect of αGC on 
exosomes in enhancing the immune response by boosting iNKT cell activity. In addition, 
splenocytes that previously had been exposed to wildtype or MHC class I lacking (MHCI-/-) 
exosomes were restimulated ex vivo using the MHC class I peptide OVASIINFEKL or whole OVA 
protein. Both groups were shown to induce IFN-γ production in similar levels, thus 
demonstrating equally potent T cell stimulation. Furthermore, we wanted to investigate the role 
of MHC molecules for their potential to reduce tumor progression in the B16-OVA melanoma 
model. For this purpose, wild type exosomes, MHCI-/- exosomes and MHC mismatched 
(allogeneic) exosomes were investigated for their tumor protective effects. All treatment groups 
had comparable levels of antigen-specific CD8+ T cell infiltration into the tumor. They also 
produced similar amounts of antigen-specific antibodies (OVA IgG) in the serum and increased 
overall survival of the mice compared to the control. Taken together, this shows that immune 
responses to exosomes are independent of MHC/peptide complex presentation in the presence 
of the whole antigen, suggesting that a direct exosome MHC/peptide complex engagement of 
T cells is not the major event taking place in vivo. Instead, it indicates that the whole exosome 
carried antigen is processed by APCs, which then presents the peptides to T cells to mount an 
immune response. Importantly, this study demonstrates the ability to use impersonalized 
exosomes for immune therapy, which would serve as a time-saving and cost-beneficial 
therapeutic approach in the clinic. 
4.1.2 Study II 
In follow-up to study I, we here further investigated the immune responses induced by the 
allogeneic exosomes and also compared the immune-stimulatory effect after two injections. 
This study demonstrate that allogeneic exosomes are more efficient than syngeneic ones in 
boosting an immune response shortly after two i.v. injections. We observed an upregulation of 
Tfh cells and antigen-specific antibody production in response to allogeneic exosomes 
compared to the syngeneic ones when investigating the immune response 14 days after initial 
immunization. Regarding their ability to induce T cell activation, we observed that, syngeneic 
and allogeneic exosomes were equally efficient in mounting an antigen-specific CD8+ T cell 
response in vivo. Moreover, splenocytes from both syngeneic and allogeneic exosome-injected 
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mice induced comparable amounts of IFN-γ upon restimulation with the MHC class I peptide 
OVASIINFEKL ex vivo. Taken together, both exosomal sources demonstrated similar capabilities 
of T cell induction. In contrast, the allogeneic exosomes displayed an increased potential to 
induce B cell responses. Notably, a significant increase in IFN-γ production upon ex vivo 
restimulation of splenocytes in response to whole OVA was only observed by splenocytes that 
had encountered the allogeneic exosomes. In addition, allogeneic exosomes generated higher 
antigen-specific antibody titers compared to syngeneic exosomes after the initial injections 
although gradually decreasing superiority of allogeneic exosomes was observed over time. 
Importantly, the antibodies generated after two injections had higher avidity and more antigen-
specific antibody producing cells i.e. plasma cells thus supporting multiple injections for 
induction of stronger immune responses when used in therapies. When mice were challenged 
with OVA protein four months after the initial exosome injections a reactivation of the immune 
response was observed. The antibody levels quickly increased, indicating the formation of an 
immune memory. However, we were not able to observe the presence of antigen-specific CD8+ 
T cells or memory T cells (CD4+/CD8+), CD62Llow, CD44high) in the spleen at the end of the 
long-term experiment. We also compared two injections of syngeneic or allogeneic exosomes 
in the B16m-OVA melanoma model. Our data demonstrate that both syngeneic and allogeneic 
exosomes induced similar levels of antigen-specific responses such as tumor infiltrating CD8+ 
T cells, antibody production, significantly delayed tumor progression and enhanced survival 
time of the mice compared to the control. In conclusion, this study shows that allogeneic 
exosomes initially induce a stronger antigen-specific immune response and markedly improve 
the amount and avidity of the antigen-specific antibodies. Furthermore, our data provides 
additional knowledge of the effects of allogeneic exosomes in vivo, and suggests their potential 
use in impersonalized immune therapies in clinical studies. 
4.1.3 Study III 
In this study, we investigated lyophilization as a novel method for loading of RAW 264.7-
derived exosomes with antigens and adjuvants to explore their immune-stimulatory capacity in 
vivo. Initially, a thorough comparison of the exosome characteristics before and after the 
lyophilization was performed to validate whether they retain exosomal properties i.e. size and 
surface marker expression. We showed that the expression levels of MHC class I and the 
tetraspanins; CD9, CD81 were preserved and at comparable levels after exosome 
reconstitution. This was followed by vesicle loading with whole OVA protein, the TLR9 ligand 
CpG-ODN and iNKT stimulating αGC, which was successfully performed and carefully 
evaluated. In order to explore whether these exosomes accomplish activation of immune cells, 
we started with investigating them in vitro. We clearly demonstrated that the OVA loaded 
RAW 264.7-derived exosomes induced CD8+ T cell proliferation in vitro by using splenocytes 
from OT-I/Rag2-/- mice. Importantly, we also detected a stronger in vitro proliferation when 
exosomes were additionally loaded with CpG-ODN and αGC, suggesting that CpG-ODN 
further stimulate DCs for improved T cell proliferation in vitro. Thereafter, we investigated 
their immune-stimulatory effect in vivo and could confirm that loaded RAW 264.7-derived 
exosomes after i.p. injection induce an overall CD4+ and CD8+ T cell proliferation, upregulate 
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antigen-specific CD8+ T cells and stimulate the production of antigen-specific antibodies in the 
serum. Moreover, we observed that tumor progression in the B16-OVA melanoma model were 
significantly reduced in response to RAW 264.7-derived exosome injections indicating their 
potential in immunotherapy. In the E.G7-OVA thymoma model, mice were initially injected 
with RAW 264.7-derived exosomes, before being challenged with the tumor cells in a cancer 
vaccine approach and they were proven to strongly prevent tumor establishment. Essentially, 
RAW 264.7-derived exosomes were confirmed to induce strong antigen-specific immune 
responses and presented a tumor reducing capacity, and thus provide an alternative method for 
exosomal loading for the development of novel cancer therapies. 
4.1.4 Study IV 
In the present study, we examined the feasibility to use the antibody-based PEA method for the 
investigation of exosomal protein levels and the ability to trace the exosome origin. 
Consequently, we analyzed protein content of several cell lines and their exosomes and 
additionally human body fluid-derived exosomes from healthy donors. We applied different 
protein panels related to cancer, cardiovascular diseases and inflammation to investigate their 
potential use for the analysis of exosomal protein content. We identified proteins that differed 
between cell lines and their corresponding exosomes, indicative of a selective loading of certain 
proteins into the exosomes. We also detected shared protein profiles, demonstrating traceability 
of exosomes back to their respective cell or tissue of origin, which is important for the use of 
exosomes as disease markers, where identifying their cellular source could be of importance. 
In addition to the use of cell lines and their originated vesicles, we also explored if human body 
fluid-derived exosomes, breast milk and seminal fluid, from healthy individuals could be 
analyzed using the PEA technology. Importantly, we found different protein profiles in the 
breast milk-derived exosomes compared to the prostate-derived exosomes, which is interesting 
from a biomarker perspective. This study demonstrates the feasibility of PEA in detecting 
proteins in human body fluid-derived exosomes. The high sensitivity and low sample 
requirement achieved by PCR amplification of the target proteins, promotes the use of PEA as 
a possible analytical and screening tool. Exosome samples contain a large number of proteins 
that may reflect the health status of the cells they originate from, this study successfully 
demonstrates their future potential as biomarkers in a clinical setting and that the PEA 
technology can be applied for this purpose. 
4.2 Discussion 
4.2.1 Antigen internalization and loading onto exosomes 
The cellular uptake and processing of free antigens is well established, although the mechanism 
for how DCs indirectly load antigens onto exosomes is currently not fully known. Antigen 
processing might vary, and therefore the efficiency of antigen loading to exosomes might 
fluctuate. Antigen uptake may occur via the specific clathrin-mediated endocytosis, or by the 
unspecific micropinocytosis, dependent on cell type and the specific antigen (19). Free OVA 
is mainly taken up specifically via the mannose receptor expressed on DCs. Therefore, an 
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efficient antigen uptake is observed by BMDCs, which will prompt peptide processing and 
loading onto MHC class II molecules (205). Endosomal escape of the antigen and cross-
presentation will facilitate the loading of peptides onto MHC class I molecules (20, 21, 206, 
207). We performed indirect loading of BMDC-derived exosomes (study I and II) by which, 
the receptor-mediated antigen internalization accomplish loading of OVA to the exosomal 
surface, but may also lead to presence of antigen inside the exosomes which remains to be 
explored. In contrast, the RAW 264.7 cell line (study III) was not capable of efficient OVA 
uptake nor loading onto their exosomes. We have previously explored the ability to load OVA 
to other cell lines such as DC 2.4 and MuTuDC (unpublished data) with the overall aim to find 
cell lines suitable for antigen loading and exosome production in a larger scale to overcome 
batch variations. Regrettably, OVA presence was not identified on these cell line-derived 
exosomes. 
Notably, our approach to load exosomes (study I and II) is limited to antigens that can be 
produced in high amounts, and therefore this loading strategy is not applicable to all antigens. 
Today, it remains to be further explored exactly how exosomes stimulate immune responses, 
and for this purpose, OVA still serves as a useful model in mice to follow antigen-specific 
immune responses in vivo. However, it is not known if the same mechanism for immune 
stimulation is applicable to all other antigens loaded to exosomes. We speculate that, at least 
partly, other antigens can be loaded to exosomes and induce similar effects in vivo, since 
exosomes themselves also provide costimulation important for inducing immune activation 
independently of the antigen-loaded. Individual antigens might also provide slightly different 
immune-stimulatory mechanisms depending on protein size, receptor specificity and loading 
efficiency onto the exosomes. 
Furthermore, we also investigated if indirect loading of exosomes could be applied using other 
antigens. Here, we explored the loading of BMDC-derived exosomes using the hen egg-white 
lysozyme (HEL) shown to be processed by DCs. However, HEL uptake is not facilitated 
through specific receptor-mediated uptake, but solely rely on micropinocytosis, which offers a 
less efficient uptake (208, 209). We could verify the presence of HEL protein on our exosomes 
using both ELISA (data not shown) and western blot, although in limited amounts probably 
related to the indirect uptake (figure 8A). Another possibility could be that HEL is processed 
differently compared to OVA and are not loaded to exosomes in the same degree, which may 
partly be related to the protein size, intracellular processing mechanisms and peptide 
presentation, which were not assessed in the present study. We investigated the immune-
stimulatory capacity of HEL loaded exosomes in vivo. Unfortunately, probably due to the 
limited antigen loading efficiency, we could not detect a sufficient IFN-γ secretion in response 
to splenocyte restimulation ex vivo using whole HEL protein, as most mice had IFN-γ levels 
similar to the controls (figure 8B). Moreover, no antigen-specific antibodies were detected in 
serum after injection of HEL loaded exosomes (data not shown). Interestingly, we observed an 
increased GC B cell response to the HEL loaded exosomes (figure 8C). Similar results, 
especially in response to unloaded exosomes, have been previously observed (210). We 
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speculate that this is caused by an unspecific immune activation towards an unknown antigen 
carried by the vesicles, e.g. fetal bovine albumin. 
 
Figure 8. Indirect loading of BMDCs with HEL protein, followed by in vivo and ex vivo investigation of their 
immune-stimulatory potential. 40 µg exosomes PBS, free HEL, B6 exo-HEL or BALB/c exo-HEL injected i.v. in 
C57Bl/6 female mice. A) BMDC-derived exosomes carry HEL. B) IFN-γ secretion upon ex vivo restimulation of 
splenocytes. C) GC B cells after injection of HEL loaded exosomes. Data are pooled from 2 independent 
experiments, 9 mice/group. 
These preliminary data suggest that it may be difficult to load other antigens to exosomes and 
an inefficient antigen loading limits the ability to study the exosomal immune-stimulatory 
capacity. More efficient loading strategies needs to be developed. Hence, lyophilization (study 
III) provides an alternative loading strategy, which is independent of cellular antigen uptake 
and reduces the amount of antigen required due to the high loading efficiency. Furthermore, 
lyophilization facilitates loading of adjuvants such as CpG-ODN for enhanced exosomal 
immune-stimulatory effect without changing the cell properties. Importantly, we show that 
exosomes loaded with CpG-ODN and treated with DNase are able to stimulate immune 
responses, proposing that CpG-ODN can be successfully loaded into the exosomes by 
lyophilization (study III). Loading of exosomes suggests a higher immune stimulation than if 
exosomes and stimuli/antigens would be co-administered. One possible explanation for this 
effect could be that vesicle carried OVA, CpG-ODN and αGC (study III) co-delivers the 
stimulatory signal to the same APC. Moreover, the ability to efficiently activate innate 
immunity by this technique is likely to enhance the properties of exosome-based vaccines. For 
cell fed antigens, the loading efficacy may be more batch dependent, which could be 
circumvented by the use of a standardized lyophilization procedure. Notably, alternative 
exosome loading, investigated by others, includes molecular engineering of cell lines for the 
expression of selected molecules for enhanced/specific immune activation and target cell 
specificity. 
4.2.2 Exosomal uptake in vitro and in vivo 
When comparing exosome T cell activation, varying observations are reported in the literature. 
T cell epitopes alone are sufficient in some studies and in others whole antigen or B cell 
epitopes are needed. T cell receptor affinity for the antigen presented by the MHC molecule 
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may vary in different models. Moreover, the exosomes themselves potentially also provide 
diverse costimulatory receptors and their activating capacity will also have an impact on the 
final conclusions drawn in different studies. For example, it has been demonstrated that DCs 
are crucial for the exosome immune activation in vivo (156) and in vitro for stimulation of T 
cells (152, 153, 157). Supporting the conclusion of exosome uptake in vivo by APCs, it has 
been demonstrated that exosomes are taken up by immature DCs for processing and peptide 
presentation on their MHC class II molecules (138). Furthermore, BMDC-derived exosomes 
primarily target the liver, followed by the spleen, gut and lungs in vivo in mice after i.v. 
injection (211). We observed that short after i.v. exosome injection MHC class II expression 
was upregulated on splenic DCs, macrophages and monocytes (study I). Moreover, we have 
previously shown that BMDC-derived exosomes bind or co-localize mainly with MZB, DCs 
and also to some extent with macrophages and FOB in vitro, however exosomes were not found 
associated with T cells (180). In study III, we observed that RAW 264.7-derived exosomes 
were mainly taken up by tissue resident macrophages and, to a smaller extent, by neutrophils 
and B cells after i.p. injection (data not shown). Taken together, this demonstrates that the 
injection route is important for the outcome of the studies performed, thus diverse results 
related to different injection routes have been discussed previously (212). Interestingly, in a 
recent study i.v. and i.p. injections were compared in tumor bearing mice, where i.v. injected 
DEX were shown slightly more efficient in reducing tumor growth (213). Moreover, our own 
in vitro data (study III), using the OT-I/Rag2-/- mice show that RAW 264.7-derived exosomes 
induce T cell proliferation in a splenocyte culture. Notably, due to different MHC background, 
the OVA transgenic CD8+ T cells are not able to respond directly to exosomes presenting the 
specific MHC class I peptide. This further suggests that also in vitro, DCs are likely responsible 
for exosome uptake and antigen presentation to T cells in our model, as these mice also lack 
functional B cells. In addition, adding CpG-ODN to the exosomes for in vitro stimulation 
further enhances proliferation suggesting the engagement of DCs (study III). 
4.2.3 Exosomes in immunotherapy 
Various immunotherapeutic strategies have been developed and tested in mouse models and in 
clinical trials, unfortunately we have not yet managed to develop therapies that are able to 
induce strong CTL responses in humans and the results observed in the mouse studies have not 
been fully reproducible in humans so far. Exosomes provide a cell-free alternative with some 
advantages compared to cells-based therapies, which support further investigation of 
exosomal-based immunotherapies. Especially, the use of DEX provide a prominent treatment 
option as they share immune-stimulatory characteristics with DCs however they can be 
produced in a larger scale and long-term storage is possible as exosomes are stable compare to 
cells. They also provide a longer half-life in circulation upon injection compared to their 
parental cell and are not prone to change characteristics due to the immune suppressive 
environment in the tumor. An efficient exosome-based anti-tumor immune therapy requires the 
activation of both innate and adaptive immune cells. In previous studies, we have shown that 
BMDC-derived exosomes can be loaded with antigens and that they are able to stimulate 
immune cells such as T cells both in vitro and in vivo. The rationale of using exosomes for 
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antigen transport is that the free antigens themselves are mostly not immunogenic, and most 
adjuvants developed to date are for viral diseases. We have repeatedly shown in our model that 
injection of free antigen in naïve mice will not trigger immune activation, suggesting that 
exosomes are important delivery vehicles for mounting an immune response towards the 
exosome carried antigens. Interestingly, we demonstrate in the long-term memory experiments 
that mice only respond to free OVA if they previously encountered the exosome carried antigen 
(study II). This finding suggests that the initial exosome injection potently stimulate naïve T 
cells. Then upon additional injections, antigen-specific T cells are present and therefore mice 
will respond to the free OVA. 
4.2.3.1 Dendritic cell-derived exosomes in immunotherapy 
In study I and II, BMDC-derived exosomes were investigated in mouse models for their 
immune-stimulatory role. Several clinical trials have been conducted, exploring peptide-loaded 
monocyte-derived dendritic cell exosomes or ascites-derived exosomes, respectively, in phase 
I clinical trials (175, 176, 181) and one phase II clinical trial (177). They were shown safe to 
administer however without inducing CTLs or presenting a sufficient tumor regression in the 
patients. The reason for the limited success in the trials applying DC-derived exosomes might 
be the use of peptides as mentioned earlier, but also related to the DC culture conditions for the 
generation of immune-stimulatory exosomes. The first trials used immature DC-derived 
exosomes followed by the most recent clinical trial which used IFN-γ matured DC-derived 
exosomes which appeared to be more potent immune stimulators. Also, the health status of the 
patients will affect the outcome of these trials, as they had progressed tumors when offered the 
treatment. Indeed, cancer patients are commonly immune suppressed, which limits the efficacy 
of exosomal treatment (35). 
4.2.3.2 Allogeneic exosomes in immunotherapy 
Stronger antigen-specific T cell responses have been observed in response to whole antigen-
loaded compared to the peptide-loaded exosomes, both for the activation of CD4+ T cells (160) 
and CD8+ T cells (180), and both responses were dependent on B cells. The ability of BMDC-
derived exosomes to stimulate T cells in vivo was enhanced in the presence of DCs, while in 
vitro exosomes alone were able to induce T cell proliferation (153, 160). We asked whether 
exosomal MHC/peptide complexes are important for antigen-specific immune responses in 
vivo. If this would be the case, exosomes would either interact directly with T cells or via cross-
dressing of the MHC/peptide complexes for T cell stimulation (figure 9A and B). If not, the 
host DC would process the exosome/antigen (figure 9C), which would open up the possibility 
to use impersonalized exosome treatments. Therefore, we first studied the role of MHC class I 
molecules on exosomes by using MHC class I deficient mice, followed by exploring allogeneic 
exosomes in our tumor model (study I). We clearly demonstrated that MHC/peptide 
presentation was not important in vivo in the presence of whole antigen and the absence of 
MHC class I or MHC mismatch still provided tumor suppression. Allogenicity was further 
examined and we demonstrated a stronger short-term immune activation in response to two 
injections, however similar long-term responses in the tumor models were seen (study I and 
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II). Since then, allogeneic DEX have been further investigated for their tumor regressing 
capacity in a hepatocellular carcinoma mouse model. They were shown to influence the TME 
by enhancing IFN-γ and IL-2, inhibit IL-10 and TGF-β secretion and downregulate Tregs in 
the tumors (213). Thus, this study confirms our findings and further strengthen our hypothesis 
that allogeneic exosomes may work in cancer immunotherapy by processing of exosome 
carried antigens for peptide presentation on the host’s own MHC molecules (figure 9C). 
Moreover, CD4+ T cell activation and Th1 cytokine secretion by exosomes were recently 
explored in vitro in an allogeneic setting (155), suggesting the use of allogeneic exosomes for 
the delivery of antigens. Of note, RAW 264.7-derived exosomes (study III) were also 
allogeneic, which strengthen the conclusions about the use of allogeneic exosomes in our 
models. Together all findings (study I-III) support the use of allogeneic exosomes as they 
demonstrate sufficient immune activation and tumor suppression. Moreover, allogenicity have 
been investigated in previous studies. For example, it has been shown that allogeneic exosomes 
are not able to directly activate T cells in vivo (159), although capable of delivering antigens 
for processing and presentation by MHC complexes on host DCs for activation of allo-reactive 
T cells (138). Notably, the ability to use allogeneic exosomes in therapies would provide an 
easily accessible and cost-beneficial approach. 
 
Figure 9. Potential exosome interaction and activation of T cells. A) Exosomes can directly interact with CD8+ T 
cells for activation. B) Exosomes can be taken up by DCs and the MHC/peptide complex can be reused i.e. “cross-
dressed” for CD8+ T cell stimulation. C) Exosomes can be taken up and the exosome carried antigen can be 
processed for peptide presentation on the DCs own MHC complexes to activate CD8+ T cells. Both scenario A 
and B require the presence of MHC class I expression on the exosomes, scenario C on the other hand, only require 
that the host have functional MHC molecules for antigen presentation. Thus, study I show that scenario C is most 
likely to occur in vivo. 
4.2.3.3 Innate activation in the tumor model 
DEX can activate the immune system in many different ways, for example by naturally loaded 
costimulatory molecules present on the exosomes and also additional antigens and adjuvants 
loaded onto the exosomes (study I-III). This thesis mainly focused on exploring the adaptive 
immune cells activated by exosomes. In our mouse models however we also see a strong effect 
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on tumor regression already within 2-3 days after BMDC-derived exosome injection, thus 
suggesting an innate immune stimulation. This may partly be induced by iNKT cell activation 
provided by the αGC delivered by the exosomes, which increase IFN-γ production and thereby 
also further stimulate an adaptive response i.e. effector cell upregulation. As discussed 
previously, the use of free αGC investigated in clinical trials induced iNKT cell anergy after 
the first injection (14, 52, 53), this was not observed when αGC was carried by the exosomes 
(182), and similar results have been observed for nanoparticles loaded with αGC. We observed 
a αGC stimulated iNKT cell proliferation, which is in line with previous findings (182). In 
addition, exosomes serve as natural adjuvants as they carry NK cell ligands and are able to 
stimulate innate immune responses and ADCC mediated NK cell killing of tumor cells, which 
is important for inhibiting tumor progression (178, 214). The survival of the mice could 
potentially be improved by the use of multiple injections to repeatedly boost the innate effector 
cells. In addition, we also explored the loading of the innate stimuli CpG-ODN onto exosomes 
for an improved immunogenicity. We found that CpG-ODN on exosomes strongly supported 
the anti-tumor immune responses in our model (study III). NK cell activation was also observed 
in the clinical trials performed using IFN-γ matured DEX. Many studies have focused on the 
induction of adaptive immune responses upon exosome injection. In order to mount potent 
adaptive responses, this also require strong initial innate responses. The role of innate versus 
adaptive immunity in our model remains to be explored in future studies.  
4.2.3.4 Humoral responses to exosomal therapies 
We explored the short-term in vivo response after a single exosome injection, and the 
experiments were terminated at day 7 before the induction of a strong humoral response (study 
I). This was followed by the investigation of antibodies in serum after repeated exosome 
injections, where we observed induction of antigen-specific antibodies (study II). Importantly, 
a ratio of IgG2c/IgG1 above 1 suggests a Th1 biased immune response, in accordance with 
previous findings (160, 182). This was induced by both syngeneic and allogeneic exosomes 
although the allogeneic exosomes were strongly enhancing the production of antigen-specific 
antibodies. This further strengthens the use of allogeneic exosomes in immune therapies against 
cancer. The antibody titers were followed over time for the comparison of syngeneic and 
allogeneic exosomes and to explore the long-term protection (study II). Importantly, the levels 
of total IgG were similar in all treatment groups (study I-II), suggesting that the antibody 
induction seen was related to a specific immune stimulation towards a specific antigen, and not 
an unspecific response. Moreover, we addressed the question whether allogeneic exosomes 
induced anti-MHC antibodies by mounting an immune response against the foreign MHC 
molecule present on the exosomes (study II). Indeed, our experiments detected serum 
antibodies specific towards the MHC class I molecules. Importantly, in serum from the long-
term experiments, these antibodies were no longer detectable, suggesting a transient allo-
recognition although no induction of long-term allogenicity (data not shown). 
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4.2.3.5 Improving exosome-based immunotherapy 
We mainly focused on the role of antigen-specific CD8+ T cell responses and iNKT cell 
engagement when using αGC on the exosomes (study I). The improved immune activation in 
response to αGC has been explored previously (182). We confirm the beneficial effect of αGC 
on the exosomes, and also show that exosomes lacking the MHC/peptide complex are 
functional in the presence of whole antigen. Future studies should aim at identifying tumor 
antigens that can be loaded onto exosomes in sufficient amounts, and development of methods 
that facilitates an efficient loading of antigens, such as shown for lyophilization (study III). 
Also, the use of allogeneic exosomes could open up the possibility to use transfected cell lines 
loaded with antigens which would provide a defined system for antigen loading onto the 
exosomes, such strategies are currently investigated. One example is the use of tumor cell line 
engineered to carry CpG-ODN on the exosomes, which were able to induce a strong anti-tumor 
effect in vivo (215). Moreover, combining exosomes with other immunotherapeutic strategies, 
such as immune-checkpoint inhibitors may improve their therapeutic effect. In fact, our 
preliminary data suggest that exosomes together with anti-CTLA-4 antibody treatment might 
provide a successful combination. However, this require further investigation. Taken together, 
several immunotherapeutic approaches are currently being tested in various combinations, as 
they will all hit diverse pathways of immune activation, their combined effect may be beneficial 
in the clinic. Also, since many of the currently available treatment options are associated with 
severe side effects, the use of suboptimal doses might be an alternative in combination with 
other treatments. 
4.2.3.6 Tumor cell-derived exosomes in immunotherapy 
The dual role of tumor cell-derived exosomes, both stimulatory and inhibitory, are described 
in the introduction. Thus, one can ask whether TEX provides a good treatment strategy in 
cancer immunotherapy as it is challenging to predict the outcome of such treatment due to 
different status/mutations of cancer cells. It has been suggested that the role of TEX in the TME 
is mainly to induce immune suppression. TEX are able to deliver tumor antigens to DCs and 
enhance their antigen presenting capacity, which would suggest the possibility to use TEX in 
cancer immunotherapy (171). When TEX are loaded to DCs, they may provide immune 
activation by providing costimulation, deliver tumor antigens to the DCs and by TEX 
selectively targeting MHC class II positive cells to activate CD4+ T cells (163, 216).  
4.2.3.7 Alternative immunotherapies  
Passive immunotherapies like antibodies or T cells only induce weak immune responses and 
low memory T cell formation and therefore provides a limited vaccine effect. Instead, active 
therapies using DCs striving to achieve both CD4+ and CD8+ T cell activation, which drive 
memory and effector T cell formation, for improved vaccine properties. DC-based therapies 
have been extensively explored in clinical trials although struggling with some limitations, for 
example, DCs may change phenotype after injection due to the immune suppressive TME. 
Moreover, many cell-based vaccines produced are not of high enough quality to be reinfused 
into the patient. 
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4.2.4 Exosomes as diagnostic markers for disease 
The use of exosomes as diagnostic markers for diseases have several advantages, for example 
various markers and protein patterns can be found in different combinations on the same 
exosome. The proteins carried by exosomes are concentrated after exosome isolation and are 
therefore measurable at higher levels compared to the levels observed in circulation, where 
specific proteins can also be masked. Moreover, exosomes may be traced to their cellular origin 
and provide information about cells or tissues without the need of invasive sampling. A lot of 
attention in the exosome field has focused on investigating exosomes as diagnostic tools due 
to their presence in different body fluids such as serum (91), plasma (101), milk (98), sputum 
(99) among others. Altered levels of exosomes and their cargo have been associated with a 
wide range of diseases, e.g. in bronchoalveolar lavage fluid of sarcoidosis patients (187), 
plasma and urine in cancer patients (100, 188), Alzheimer’s disease (189) and cardiovascular 
diseases (190). The finding that exosomes carry mRNA and miRNA made them even more 
interesting from a biomarker perspective (121, 125, 170). The use of plasma-derived exosomes 
for biomarker discovery has been complicated due to the co-isolation of exosomes with the 
lipoproteins present in plasma. A recent study identified that SEC along with density gradient 
could serve as a possible method to eliminate the contaminating lipoproteins before performing 
proteomic analysis using mass spectrometry (217). In study IV, we focused on the use of 
exosomes for biomarker discovery exploring PEA as a sensitive tool to analyze the proteome 
of exosomes. Exosomal proteins have formerly been examined using multiple sources and 
methods (98, 144, 168, 194, 195, 218), thus many similarities in the proteins detected are shared 
with our present findings (study IV). The exosome field requires more sensitive proteomic 
methods as sample amounts often restricts the possibility to run a full proteomic analysis. The 
advantage with multiplex PEA compared to other available proteomic methods is the high 
specificity and sensitivity due to dual recognition via antibody-based detection of the proteins 
and signal amplification via PCR. In addition, the low sample volume requirement makes the 
method suitable for proteome analysis of exosomes (218-223). Furthermore, other screening 
methods are more time consuming, with limited reproducibility and not optimized for high-
throughput analysis (224). We compared cell lines and their exosomes, and also body fluid-
derived exosomes for examining the feasibility of using PEA on human exosome samples. We 
clearly demonstrate that PEA is useful in this aspect although struggling with the obvious 
limitations of being a biased method due to the selected antibodies used. Notably, the risk for 
false positive signals is limited since the two antibodies applied needs to be matched to 
hybridize and induce the PCR amplification, which have been carefully evaluated previously 
(225). Another disadvantage is the varying affinities of the antibodies therefore comparing 
different protein amounts is not achievable with the current setup. Importantly, due to the high 
sensitivity of PEA, this complicates the validation using other techniques. The next step in the 
aim of finding disease biomarkers would be to use PEA in a broader screening of patients and 
healthy individuals to identify exosomal protein patterns that can be linked to disease and/or 
prognosis. 
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4.2.5 Concluding remarks 
The obstacles with cell-based therapies, previously emphasized, can be circumvented by the 
use of “off the shelf”-treatments such as exosomes. Exosome-based immunotherapy has been 
investigated in clinical trials although without a sufficient anti-tumor response, suggesting that 
the functional effects of exosomes need further investigation. The combination of several 
immune-stimulatory signals delivered by exosomes might potentiate their function as vaccines 
by the induction of both the innate and the adaptive immune responses. Moreover, 
impersonalized exosome immunotherapies would be of advantage by improving the treatment 
availability and lower the production cost. Notably, one limitation has been the need for an 
autologous system. However, it has been suggested that an allogenic system might work well 
without severe side effects (179). Our studies also support the beneficial use of allogeneic 
exosomes in immunotherapy.  
Another suggested approach, not previously discussed, is to use exosomes as drug delivery 
vehicles. Exosomes have several properties that makes them interesting as target vesicles for 
drug delivery, e.g. they are small enough to cross the blood brain barrier and they target specific 
cells depending on their surface marker expression. In addition, exosomes can also reach 
distant targets with high specificity (226) and they are stable in vivo and in vitro (227). 
Moreover, novel exosome isolation methods are currently being developed, which will 
improve exosome research by providing ways to investigate purified exosomes from biological 
fluids and the possibility to select for certain vesicle populations. Currently available isolation 
methods restrict the ability to study individual exosomes and independent of the isolation 
method of choice, they all have their limitations. Furthermore, exosomes carry the potential to 
serve as biomarkers for disease. The advantage of applying exosomes as biomarkers are their 
noninvasive sampling due to their presence in body fluids, and also the accumulation of certain 
markers in the vesicles. Higher sensitivity in different approaches such as proteomics will 
increase the feasibility of using exosomes as biomarkers, and the ability to link the exosome 
phenotype to disease prognosis. At present, several clinical trials examining exosomes as 
biomarkers are currently ongoing, which will hopefully reveal potential exosomal biomarkers. 
In conclusion, improved vaccination strategies might in the future lead to strong exosome-
based cancer vaccine candidates. This requires development of novel technologies allowing 
efficient antigen loading of exosomes and further studies assessing the exosomal potential in 
clinical trials. Thus, this thesis suggests that allogeneic exosomes are a safe alternative 
treatment strategy and that they are potent inducers of immune responses. Moreover, this thesis 
also suggests a novel method for antigen loading of exosomes and also propose PEA as a highly 
sensitive method for exosomal proteomic analysis, which may be applied in future exosomal 
biomarker discoveries. 
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